3 Comments

CHAPTER 45 GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY AND OTHER RED CELL ENZYME ABNORMALITIES

CHAPTER 45 GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY AND OTHER RED CELL ENZYME ABNORMALITIES
Williams Hematology

CHAPTER 45 GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY AND OTHER RED CELL ENZYME ABNORMALITIES

ERNEST BEUTLER

Definition and History
Etiology and Pathogenesis

The Mechanism of Hemolysis

Biochemical Genetics and Molecular Biology

Other Enzyme Deficiencies
Prevalence, Geographic Distribution, and Population Genetics
Clinical Features

Common Forms of G-6-PD Deficiency

Hereditary Nonspherocytic Hemolytic Anemia
Laboratory Features
Differential Diagnosis
Therapy, Course, and Prognosis

Therapy of G-6-PD Deficiency

Splenectomy in Nonspherocytic Hemolytic Anemia

Glucocorticoids

Course and Prognosis
Chapter References

Erythrocyte enzyme deficiencies may lead to hemolytic anemia and sometimes to other systemic pathology. G-6-PD deficiency is the most common of these. In some populations more than 20 percent of the population may be affected by this enzyme deficiency. In the common polymorphic forms, such as G-6-PD A–, G-6-PD Mediterranean, or G-6-PD Canton, hemolysis occurs only during the stress imposed by infection or administration of “oxidative” drugs, and in some individuals upon ingestion of fava beans. Neonatal icterus, which appears largely to be due to a defect in bilirubin conjugation, is the clinically most serious complication of G-6-PD deficiency. Patients with less common, functionally very severe, genetic variants of G-6-PD experience chronic hemolysis, a disorder designated hereditary nonspherocytic hemolytic anemia.
Hereditary nonspherocytic hemolytic anemia also occurs as a consequence of other enzyme deficiencies, the most common of which is pyruvate kinase deficiency. Glucosephosphate isomerase, triosephosphate isomerase, and pyrimidine-5′-nucleotidase deficiency are included among the relatively rare causes of hereditary nonspherocytic hemolytic anemia. In the case of some deficiencies, notably those of glutathione synthetase, triosephosphate isomerase, and phosphoglycerate kinase, the defect is expressed throughout the body and neurologic defects may be a prominent part of the clinical syndrome.
Diagnosis is best achieved by determining red cell enzyme activity either with a quantitative assay or a screening test. Except for the stippling of erythrocytes that is characteristic of pyrimidine-5′-nucleotidase deficiency, red cell morphology is of little or no help in differentiation of red cell enzyme deficiencies from one another. A variety of molecular lesions have been defined in most of these enzyme deficiencies. Accurate diagnosis is helpful in recommendations for treatment, since patients with some enzyme deficiencies (e.g., glucosephosphate isomerase deficiency) tend to respond more favorably to splenectomy than patients with other deficiencies (e.g., G-6-PD deficiency). It is also essential for genetic counseling since some of the defects, such as pyruvate kinase and glucosephosphate isomerase deficiencies, are transmitted as autosomal recessive disorders, while G-6-PD and phosphoglycerate kinase deficiencies are X-linked.

Acronyms and abbreviations that appear in this chapter include: AD, autosomal dominant; AMP, adenosine monophosphate; G-6-PD, glucose-6-phosphate dehydrogenase; GR, glutathione reductase; GSH, glutathione; GSSG, glutathione disulfide; HNSHA, hereditary nonspherocytic hemolytic anemia; ITP, inosine triphosphate; NAD, nicotinamide-adenine dinucleotide; NADP, nicotinamide-adenine dinucleotide phosphate; NADH, reduced nicotinamide-adenine dinucleotide; NADPH, reduced nicotinamide-adenine dinucleotide phosphate; PCR, polymerase chain reaction; PK, pyruvate kinase; TPI, triosephosphate isomerase.

DEFINITION AND HISTORY
Deficiencies in the activities of a number of erythrocyte enzymes may lead to shortening of the red cell life span. G-6-PD deficiency was the first of these to be recognized and is the most common.
The recognition of G-6-PD deficiency was the result of investigations of the hemolytic effect of the antimalarial drug primaquine, carried out in the 1950s and described in detail elsewhere.1,2 and 3 These early studies defined G-6-PD deficiency as a hereditary sex-linked enzyme deficiency that affected primarily the erythrocytes, older cells being more severely affected than newly formed ones. They showed that this enzyme deficiency was very prevalent in individuals of African, Mediterranean, and East Asian ethnic origins, but that it could be found in virtually any population. The common (polymorphic) forms of G-6-PD deficiency were found to be associated with anemia only under conditions of stress, such as the administration of oxidative drugs, infection, or the neonatal period.
Chronic hemolysis in the absence of a stress occurs in uncommon, functionally severe forms of G-6-PD deficiency and in patients with a variety of other red cell enzyme deficiencies. Such patients have hereditary nonspherocytic hemolytic anemia. Although patients fitting the description of hereditary nonspherocytic hemolytic anemia had been documented earlier, the designation was first introduced by Crosby4 in 1950. Dacie and his colleagues5 subsequently reported several families in which affected members manifested hemolytic anemia from an early age and in whom the osmotic fragility of the red cells was normal. The latter finding, and the fact that most of the affected individuals failed to benefit from splenectomy, distinguished this disorder from hereditary spherocytosis. Thus, defined essentially by exclusion as a hereditary hemolytic anemia that is not hereditary spherocytosis, it is not at all surprising that hereditary nonspherocytic hemolytic anemia has proven to be extremely heterogeneous, both in etiology and in clinical manifestations. Sometimes this disorder is also designated congenital nonspherocytic hemolytic anemia, but the name hereditary is more accurate and is therefore preferable. While hereditary ovalocytosis, pyropoikilocytosis, stomatocytosis, and even sickle cell disease and thalassemia major are hereditary hemolytic anemias that are not spherocytic, they are not included in this category. Rather, the diagnosis of hereditary nonspherocytic hemolytic anemia is reserved for those patients who have no major aberration of red cell morphology.
Although a deficiency of G-6-PD was found to be responsible for hemolysis in a few patients with hereditary nonspherocytic hemolytic anemia,6 in the overwhelming majority of cases the cause remained obscure. In 1954 Selwyn and Dacie7 studied autohemolysis (spontaneous lysis of red cells after sterile incubation for 24 to 48 h at 37° C) in four patients with hereditary nonspherocytic hemolytic anemia and found that in two of them lysis was only slightly increased and was prevented by glucose; these patients were designated as type 1, while the others, in whom glucose failed to correct hemolysis, were classified as type 2. Autohemolysis of the erythrocytes of type 2 patients was modified by the addition of ATP, a substance that we now recognize does not penetrate the red cell membrane. Instead, its modifying influence was probably exerted chiefly by virtue of its effect on the osmolarity and pH of the suspending solution. However, the findings suggested to De Gruchy et al8,9 that patients with type 2 autohemolysis suffered from a defect in ATP generation. This proposal, born of a misunderstanding of red cell biochemistry, turned out to be correct: one of the major causes of hereditary nonspherocytic hemolytic anemia proved to be a deficiency of the ATP-generating enzyme pyruvate kinase (PK),10 but this was only the first of a large number of enzyme defects that have been shown to account for this heterogeneous syndrome.11,12
ETIOLOGY AND PATHOGENESIS
Red cell enzyme deficiencies that cause hemolytic anemia are hereditary. Most are inherited as autosomal recessive disorders, but G-6-PD deficiency and phosphoglycerate kinase deficiency are X-linked.
The erythrocyte enzyme deficiencies that have been shown to cause hemolytic anemia and other hematologic diseases are listed in Table 45-1. Other red cell enzyme deficiencies, listed in Table 45-2, do not appear to cause a functional abnormality of the erythrocyte.13 For example, acatalasemia, the state in which there is a virtually total absence of red cell catalase, is devoid of hematologic manifestations. Similarly, red cells without cholinesterase14 seem to survive normally in most cases. The lack of clinical manifestations is not always clear-cut. In some instances hemolytic anemia is reported in some individuals with a given deficiency but not in others. For example, most subjects with lactate dehydrogenase deficiency have had no anemia, but cases with hemolysis have been reported.15 Such ambiguity could be due to differences in environmental and genetic factors, but also to the bias of ascertainment. Erythrocyte enzyme assays are usually carried out on patients with hemolytic anemia. Thus, a benign enzyme defect may be thought mistakenly to cause hemolysis because it is found in a patient with hemolytic anemia. Deficiencies of phosphoglycerate16,17 kinase and of glutathione synthetase are usually associated with hereditary nonspherocytic hemolytic anemia, but cases have been reported in which these deficiencies were unassociated with any hematologic manifestations. It has at times been suggested that moderate decreases in the activity of glutathione reductase and of glutathione peroxidase caused hemolytic anemia, but the best available evidence indicates that these enzymes are not ordinarily rate limiting in erythrocyte metabolism and are not associated with hemolytic anemia.12 Even the total absence of glutathione reductase in the red cells of members of one family was associated with only rare episodes of hemolysis, possibly caused by fava beans, in otherwise hematologically normal individuals.18 Included in Table 45-2 are deficiencies that may cause hemolytic anemia but for which a cause-and-effect relationship has not been clearly established, such as those of phosphogluconolactonase,19 enolase,20 glutathione-S-transferase,21 and adenylate kinase.22

TABLE 45-1 RED CELL ENZYME ABNORMALITIES LEADING TO HEMATOLOGIC DISEASE

TABLE 45-2 RED CELL ENZYME ABNORMALITIES NOT LEADING TO HEMATOLOGIC DISEASE

Patients with unstable hemoglobins (see Chap. 48) may present with the clinical picture of hereditary nonspherocytic hemolytic anemia. Hemolytic anemia due to abnormalities in the lipid composition of the red cell membrane, particularly increased phosphatidyl choline, occur rarely23,24,25 and 26 (see Chapter 44).
THE MECHANISM OF HEMOLYSIS
G-6-PD DEFICIENCY AND OTHER DEFICIENCIES OF HEXOSE MONOPHOSPHATE SHUNT ENZYMES
The life span of G-6-PD-deficient red cells is shortened under many circumstances, particularly during drug administration and infection. The exact reason for this is not known.
Drug-induced Hemolysis Drug-induced hemolysis in G-6-PD-deficient cells is generally accompanied by the formation of Heinz bodies, particles of denatured hemoglobin and stromal protein (see Chap. 22) formed only in the presence of oxygen.27 The mechanism by which Heinz bodies are formed and become attached to red cell stroma has been the subject of considerable investigation and speculation. Exposure of red cells to certain drugs results in the formation of low levels of hydrogen peroxide as the drug interacts with hemoglobin.28 In addition, some drugs may form free radicals that oxidize GSH without the formation of peroxide as an intermediate.29 The formation of free radicals of GSH through the action of peroxide or by the direct action of drugs may be followed either by oxidation of GSH to the disulfide form (GSSG) or complexing of the glutathione with hemoglobin to form a mixed disulfide. Such mixed disulfides are believed to form initially with the sulfhydryl group of the b-93 position of hemoglobin.30 The mixed disulfide of GSH and hemoglobin is probably unstable and undergoes conformational changes exposing interior sulfhydryl groups to oxidation and mixed disulfide formation. Globin chain separation into free a and b chains also occurs.31 Phenylhydrazine-like drugs also have been shown to form a hemochromogen directly with hemoglobin, a complex forming between the iron of ferriheme and the nitrogen bound to the benzene ring of the drug.32 Once such oxidation has occurred, hemoglobin is denatured irreversibly and will precipitate as Heinz bodies. Normal red cells can defend themselves to a considerable extent against such changes by reducing GSSG to GSH and by reducing the mixed disulfides of GSH and hemoglobin through the glutathione reductase reaction.33 However, the reduction of these disulfide bonds requires a source of NADPH. Since G-6-PD-deficient red cells are unable to reduce NADP+ to NADPH at a normal rate, they are unable to reduce hydrogen peroxide or the mixed disulfides of hemoglobin and GSH. Moreover, because catalase apparently contains tightly bound NADPH34 that is required for activity, the lack of NADPH generation may impede an alternate pathway for the disposal of hydrogen peroxide.35 When such cells are challenged by drugs they form Heinz bodies more readily than do normal cells. Cells containing Heinz bodies encounter difficulty in traversing the splenic pulp36 and are eliminated relatively rapidly from the circulation. The metabolic events that may lead to red cell damage and eventually destruction are summarized in Fig. 45-1.

FIGURE 45-1 Reactions through which hydrogen peroxide is generated and detoxified in the erythrocyte. In G-6-PD deficiency inadequate generation of NADPH results in accumulation of GSSG and probably of H2O2. The accumulation of these substances leads to hemoglobin denaturation, Heinz body formation, and consequently to decreased red cell survival. GR, glutathione reductase; GSH Px, glutathione peroxide; Sup Dismut, superoxide dismutase; GSSG, glutathione disulfide (oxidized glutathione).

The formation of methemoglobin frequently accompanies the administration of drugs that have the capacity to produce hemolysis of G-6-PD-deficient cells.37 The heme groups of methemoglobin become detached from the globin more readily than do the heme groups of oxyhemoglobin.38 It is not clear whether methemoglobin formation plays an important role in the oxidative degradation of hemoglobin to Heinz bodies or whether formation of methemoglobin is merely an incidental side effect of oxidative drugs.39,40
Infection-induced Hemolysis The mechanism of hemolysis induced by infection or occurring spontaneously in G-6-PD-deficient subjects is not well understood. It has been suggested that the generation of hydrogen peroxide by phagocytizing leukocytes may play a role in this type of hemolytic reaction.40 Substances capable of destroying red cell GSH have been isolated from fava beans.41 Favism occurs only in G-6-PD-deficient subjects, but not all deficient individuals in a particular family may be sensitive to the hemolytic effect of the beans. Nonetheless, some tendency toward familial occurrence has suggested the possibility that an additional, genetic factor may be important.42 The observation of increased excretion of glucaric acid43 led to the suggestion that a defect in glucuronide formation might be present. An excess of individuals with the acid phophatase ACP1 A/C genotype has been found and attributed to a decrease in the f isoform of this tyrosine phosphatase.44 Immunologic factors do not seem to play a role in favism.45 Increased levels of red cell calcium46,47 and consequent “cross-bonding” of membranes may occur. Such bonding of the facing inner membrane surfaces48 may play a role in the destruction of red cells.
Neonatal Jaundice Icterus neonatorum in G-6-PD deficiency probably is due principally to inadequate processing of bilirubin by the immature liver of G-6-PD-deficient infants, although shortening of red cell life span may play a role. Anemia does not appear to be present in these infants and there is only a slight increase in CO production, signifying a minimal decrease in red cell life span.49 Severe jaundice due to G-6-PD deficiency seems to be limited to infants who have also inherited a mutation of the uridine diphosphoglucuronate glucuronosyltransferase 1 (UDPGT-1) gene promoter,50 the same mutation that in adults is associated with Gilbert syndrome. The limited data available on liver G-6-PD in deficient adults51 suggest that a considerable degree of deficiency may be present. If such a deficiency also is present in infants, it may play a role in impairing the borderline ability of infant livers with the UDPGT-1 promoter defect to catabolize bilirubin. While an increased incidence of neonatal icterus has been observed in Mediterranean infants with G-6-PD deficiency and among the Chinese,52 jaundice seems to be less common among neonates with the A– type of enzyme deficiency. Some cases have been reported in G-6-PD-deficient infants53,54 and 55 in Africa, but in the United States the incidence of jaundice in G-6-PD A– does not appear to be increased.56,57 The cause of the relatively low incidence of neonatal jaundice in infants with G-6-PD A– mutation is not clear. It could be due to the higher residual enzyme activity, but it does not appear to be related to the incidence of the UDPGT-1 promotor mutation, which is actually more common in Africans and less common in Asians than it is in Europeans.58
DEFICIENCIES OF OTHER ENZYMES OF THE HEXOSE MONOPHOSPHATE SHUNT AND OF GLUTATHIONE METABOLISM
Deficiencies of g-glutamyl synthetase59,60 and of glutathione synthetase60,61 are associated with a decrease in red cell GSH levels, and the mild hemolysis that occurs in these disorders probably has a pathogenesis similar to the hemolysis that occurs in G-6-PD deficiency. The same is probably true of the single case of glutathione reductase deficiency that has been documented.18 Other defects of the hexose monophosphate and associated metabolic pathways, such as 6-phosphogluconolactone deficiency19 and 6-phosphogluconate dehydrogenase deficiency62 are not associated with hemolysis.
OTHER ENZYME DEFICIENCIES
How deficiencies of enzymes other than those of the hexose monophosphate pathway result in shortening of red cell life span remains unknown, although it has been the object of much experimental work and of speculation. It is often believed that ATP depletion is a common pathway in producing damage to the cell leading to its destruction,63 but the evidence that this is the case is not always compelling.64 It is possible that, at least in some cases, alteration of the levels of red cell intermediate metabolites interferes with synthesis of cell components in early stages of development of the cell.
ANIMAL MODELS
G-6-PD deficiency has been encountered in rats,65 dogs,66 mice,67,68 and horses.69,70 Pyruvate kinase deficiency is polymorphic in Basenji dogs71 and has been found in mice.72,73 and 74 Phosphofructokinase deficiency causes hemolytic anemia in dogs,75 and glucosephosphate isomerase deficiency has been detected in mice.76
BIOCHEMICAL GENETICS AND MOLECULAR BIOLOGY
GLUCOSE-6-PHOSPHATE DEHYDROGENASE Biochemical Genetics
The “normal” enzyme is designated as G-6-PD B. It represents the most common type of enzyme encountered in all the population groups that have been studied. Many variants of G-6-PD have been detected all over the world. Before it became possible to characterize these variants at the DNA level they were distinguished from each other on the basis of biochemical characteristics, such as electrophoretic mobility, Km for NADP and glucose-6-phosphate, ability to utilize substrate analogs, pH activity profile, and thermal stability. To facilitate comparison of variants characterized in different laboratories, international standards for the methodology were established.77 In the case of the common G-6-PD A– and G-6-PD Mediterranean mutations, the abnormal enzyme may be synthesized at normal or near-normal rates but has decreased stability in vivo.78 The amount of enzyme antigen in the red cells declines concurrently with enzyme activity.79,80 This suggests that the mutant protein in these variants is rendered unusually sensitive to proteolysis in the environment of the erythrocyte.81 Other mutations also result in the formation of enzyme molecules with decreased enzyme activity80 and with altered kinetic properties,82 some of which may render them functionally inadequate. For example, G-6-PD Oklahoma83 manifests a marked decrease in its affinity for the substrates glucose-6-phosphate and NADP, and G-6-PD Manchester and G-6-PD Tripler84 are abnormally sensitive to the inhibitory effect of NADPH. Detailed biochemical characteristics of some 400 putatively distinct G-6-PD variants have been tabulated.85 Fig. 45-2 is a semischematic representation of the biochemical properties of two of the more common variants.

FIGURE 45-2 The biochemical properties of two common variants of G-6-PD. (a) The biochemical characteristics of G-6-PD A–. (b) The biochemical characteristics of G-6-PD Mediterranean. In each panel the characteristics of the normal enzyme (types A and B) are indicated by the shaded areas.

Molecular Biology The gene for G-6-PD is over 20 kb in length, containing 13 exons. The coding sequence begins in exon 2. The intron between exons 2 and 3 is extraordinarily long, spanning 9857 base pairs.86 Methylation of certain cytidines at the 3′ end is believed to have a regulatory function.87 The enzyme is composed of 515 amino acids, with a calculated molecular weight of 59,256. Aggregation of the inactive monomers into catalytically active dimers and higher forms requires the presence of NADP.88 Thus, NADP appears to be bound to the enzyme both as a structural component and as one of the substrates of the reaction.89,90 and 91 The glucose-6-phosphate binding site has been identified at amino acid 205 by locating a lysine that is reactive in competition with glucose-6-phosphate at this position.92,93 Examination of mutants suggested that amino acids 386 and 387 bind one of the phosphates of NADP.94 However, the crystal structure of G-6-PD from Leuconostoc mesenteroides95 is interpreted as indicating that it is actually His 201 that is the binding site, a location 36 A° distant from the 386–387 site.95
African Variants Among persons of African descent a mutant enzyme with normal activity is very prevalent. Known as G-6-PD A+, it migrates electrophoretically more rapidly than the normal B enzyme. A single amino acid substitution of Asn®Asp has been identified both by peptide analysis96 and by DNA sequencing (376 A®G).97 G-6-PD A– is the principal deficient variant found among people of African origin. The red cells contain only 5 to 15 percent of the normal amount of enzyme activity. The mobility of the enzyme present is rapid and is indistinguishable from that of the A+ variant in conventional electrophoretic systems. The fact that these two electrophoretically rapid variants are common in African populations is not a coincidence. Sequence analysis of G-6-PD A+ and G-6-PD A– has shown that these two mutations have in common a nucleotide substitution at cDNA nucleotide 376 that produces the amino acid substitution responsible for the rapid electrophoretic mobility. Most samples with G-6-PD A– manifest an additional mutation at nucleotide 202 that accounts for its in vivo instability.98 Apparently the interaction of the two mutations results in the deficiency.99 Less commonly, the additional mutation is at a different site (Table 45-3). Thus, it is evident that G-6-PD A– arose in an individual who already had the G-6-PD A+ mutation. However the ancestral human sequence has been deduced to be that of G-6-PD B, both by showing that this is the sequence of the chimpanzee,100 our nearest relative, and by analysis of linkage dysequilibrium.101

TABLE 45-3 SOME OF THE MORE IMPORTANT G-6-PD VARIANTS THAT HAVE BEEN CHARACTERIZED AT THE DNA LEVEL*

Variants in the Mediterranean Region Among Caucasian populations G-6-PD deficiency is most common in Mediterranean countries. The most common enzyme variant in this region is G-6-PD Mediterranean.82 The enzyme activity of the red cells of individuals who have inherited this abnormal gene is barely detectable. Other variants are also prevalent in the Mediterranean region, including G-6-PD A– and G-6-PD Seattle (see Table 45-3).
Variants in Asia A great many different variants have been described in East Asian populations. Some of these proved to be identical at a molecular level (e.g., G-6-PD Gifu, Agrigento, Canton, and Taiwan-Hakka all have the same mutation at cDNA nt 1376), but DNA analysis has shown that over 10 different mutations are found in various East Asian populations.102,103,104 and 105
Variants Producing Hereditary Nonspherocytic Hemolytic Anemia Some mutations of G-6-PD result in chronic hemolysis without precipitating causes. From a functional point of view these mutations are more severe than the more commonly occurring polymorphic forms of the enzyme, such as G-6-PD Mediterranean and G-6-PD A–, but the in vitro enzyme activity may actually be greater in such variants. It has been suggested that specific biochemical characteristics such as susceptibility to inhibition by NADPH might explain the chronic hemolysis that occurs in patients with such variants,84 but no unifying principle that accounts for the clinical effects of variants has been found. On a molecular level, such variants usually are located in exon 1094 or in the region of the glucose-6-phosphate binding site.106 There are, however, exceptions to this rule. For example, deletion of a triplet near the 5′ end of the coding region107 and a mutation very near the carboxy terminus of the enzyme also have been found to result in hemolysis.108
PYRUVATE KINASE
Pyruvate kinase deficiency, like G-6-PD deficiency, is genetically heterogeneous, with different mutations causing different kinetic and electrophoretic changes in the enzyme that is formed. Abnormalities include altered affinity for the substrate phosphoenolpyruvate (PEP) and the allosteric activator fructose 1,6-diphosphate (FDP).109,110,111 There are even cases in which the activity of pyruvate kinase as measured in vitro is higher than normal but a kinetically abnormal enzyme is responsible for the occurrence of hemolytic anemia.112 Kinetic characterization and analysis of pyruvate kinase mutants is considerably more complex, however, than analysis of G-6-PD mutants. Since two alleles are expressed in each cell, five different tetramers will be formed if the mutations are different: the two homotetramers and mixed tetramers containing different proportions of different subunits. Moreover, there are several different molecular forms of pyruvate kinase, formed from two different genes: the M, or muscle, type of enzyme, which is found in leukocytes and many other tissues, and the L, or liver, type of enzyme. Erythrocytes contain only a product of the L gene, designated the R type of enzyme. Thus, it is mutations of the pyruvate kinase L gene that cause hemolytic anemia. There has been international agreement on standard methods for characterizing pyruvate kinase variants,113 but because of the complexities mentioned above, the biochemical information is even less robust than that obtained with G-6-PD variants. It has been suggested that some correlation exists between the quantity and biochemical characteristics of the residual enzyme in enzyme-deficient patients and these patients’ clinical course.114
The cDNA for human L type pyruvate kinase has been cloned,115,116 and mutations identified in many deficient patients (Table 45-4).117,118 The same mutations are encountered repeatedly in apparently unrelated individuals, although the existence of a common haplotype in such persons indicates that they are presumably offspring of a common ancestor.119,120 The 1529A mutation in particular is encountered repeatedly, even in the homozygous state, in unrelated individuals.121 Deletion of exon 11 is characteristic of the mutation found among Gypsies.119 The nature of the mutation has relatively little predictive value with respect to the severity of the clinical course.120,122

TABLE 45-4 SOME PYRUVATE KINASE MUTATIONS

OTHER ENZYME DEFICIENCIES
The mutations that cause other enzyme deficiencies have been identified in many instances. Table 45-2 provides references to some of the more recent studies in which the abnormalities in DNA sequence have been documented.
PREVALENCE, GEOGRAPHIC DISTRIBUTION, AND POPULATION GENETICS
The prevalence of G-6-PD deficiency among Caucasian populations ranges from less than 1 in 1000 among northern European populations to 50 percent of the males among Kurdish Jews. G-6-PD deficiency is also found among certain Chinese populations and in Southeast Asia but it is rare in Japan. G-6-PD deficiency of the A– type is very common in West Africa, and the prevalence among African American males is approximately 11 percent.123 Some 16 percent of African American males carry the nondeficient G-6-PD A+ gene. The distribution of G-6-PD deficiency among various population groups has been presented in detail elsewhere.124,125
The high frequency of G-6-PD-deficient genes in many populations implies that G-6-PD deficiency confers a selective advantage. The suggestion126 that resistance to malaria could account for the frequency of G-6-PD deficiency was supported by studies in heterozygotes for G-6-PD A– that showed a higher degree of infestation of G-6-PD sufficient cells than of G-6-PD-deficient cells.127 It has been suggested that deficient cells infested with malaria parasites may be phagocytosed more efficiently than normal cells.128
It has been suggested129,130 that a higher prevalence of G-6-PD deficiency in individuals with sickle cell disease than in the general African population reflects a favorable effect of the enzyme deficiency on the clinical course of the sickling disorders. However, it seems that the increased prevalence of G-6-PD deficiency in patients with sickle disease may merely result from the markedly heterogeneous genetic composition of African Americans; those with more African genes are more likely to inherit sickle hemoglobin and G-6-PD A–.131,132 and 133 Similar factors may be responsible for the slight excess of G-6-PD deficiency observed among patients with SS hemoglobin in Arab populations.134
Pyruvate kinase deficiency is the most common cause of hereditary nonspherocytic hemolytic anemia. Estimates of heterozygote frequency have ranged from 0.24135 to 3.1 percent136 using screening techniques. More quantitative studies performed on a large number of cord blood samples have provided estimates of 1 percent in the white population and 2.4 percent in African Americans.137 A gene frequency of about 0.005 has been deduced from study of a large number of DNA samples from subjects of the European origin. Estimates of other deficiency alleles, such as those for adenylate kinase, diphosphoglycerate mutase, enolase, triosephosphate isomerase, and phosphoglycerate kinase have also been made on large numbers of cord bloods.137 A particularly high incidence of heterozygous TPI deficiency of over 4 percent in African Americans is supported by family studies.138 Since it is not reflected in a correspondingly high birth incidence, the allele might be lethal in the homozygous state. It was suggested that a promoter mutation at the -5 and -8 positions created such a lethal gene,139 but the finding of normal adult homozygotes for these mutations shows that this is not the case.140
In addition to the common G-6-PD mutations there are mutations in other enzymes that are repeatedly encountered in a population. Included are the 1529A mutation of pyruvate kinase,120,121 the deletion of exon 11 found among Gypsies,119 and the 1591 C mutation of TPI.141 In each of these instances the existence of each mutation in the context of the same haplotype implies that there has been a founder effect, that is, the mutation occurred only once and all individuals now carrying it are descendants of the person who sustained the original mutation. The expansion of the mutation could represent a selective advantage for heterozygotes but may also be due to random factors or to a selective advantage provided by one or more tightly linked genes.
CLINICAL FEATURES
COMMON FORMS OF G-6-PD DEFICIENCY
Individuals who inherit the common (polymorphic) forms of G-6-PD deficiency, such as G-6-PD A– or G-6-PD Mediterranean usually have no clinical manifestations. The major clinical consequence of G-6-PD deficiency is hemolytic anemia in adults and neonatal icterus in infants. Usually the anemia is episodic, but some of the unusual variants of G-6-PD may cause hereditary nonspherocytic hemolytic disease (see below). In general, hemolysis is associated with stress, most notably drug administration, infection, and, in certain individuals, exposure to fava beans.
DRUG-INDUCED HEMOLYTIC ANEMIA
A large number of drugs and other chemicals that may have the capacity to precipitate hemolytic reactions in G-6-PD-deficient individuals are listed in Table 45-5. Some drugs, such as chloramphenicol, may induce mild hemolysis in a person with severe, Mediterranean-type G-6-PD deficiency142 but not in those with the milder A– or Canton143 types of deficiency. Drugs that are innocuous when given in normal doses (Table 45-5) may be hemolytic when given in excessive doses. A case in point is ascorbic acid, which does not cause hemolytic anemia when even as much as 40 g is given intravenously,144 but which can produce severe, even fatal, hemolysis at doses of 80 g or more intravenously.144,145 and 146 There appears, furthermore, to be a difference in the severity of the reaction to the same drug of different individuals with the same G-6-PD variant. For example, red cells from a single G-6-PD-deficient individual were hemolyzed in the circulation of some recipients who were given thiazolsulfone, but their survival was normal in the circulation of others.27 Sulfamethoxazole, which was clearly hemolytic in experimental studies, does not appear to be a common cause of hemolysis in a clinical setting.147 Undoubtedly, individual differences in the metabolism and excretion of drugs influence the extent to which G-6-PD-deficient red cells are destroyed.148,149

TABLE 45-5 DRUGS AND CHEMICALS THAT SHOULD BE AVOIDED BY PERSONS WITH G-6-PD DEFICIENCY*

Typically, an episode of drug-induced hemolysis in G-6-PD-deficient individuals begins 1 to 3 days after drug administration is initiated.150 Heinz bodies appear in the red cells, and the hemoglobin concentration begins to decline rapidly.151 As hemolysis progresses Heinz bodies disappear from the circulation, presumably as they or the erythrocytes that contain them are removed by the spleen. In severe cases abdominal or back pain may occur. The urine may turn dark—even black. Within 4 to 6 days there is generally an increase in the reticulocyte count, except in instances in which the patient has received the offending drug in treatment of an active infection. Because of the tendency of infections and certain other stressful situations to precipitate hemolysis in G-6-PD-deficient individuals, many drugs have been incorrectly implicated as a cause. Other drugs, such as aspirin, have appeared on many lists of proscribed medications because very large doses could slightly reduce the red cell life span. It is important to recognize that such drugs, listed in Table 45-6, do not produce clinically significant hemolytic anemia. Advising patients not to ingest these drugs may not only deprive patients of potentially helpful medications but will also weaken their confidence in the advice that they have received. Most G-6-PD-deficient patients, after all, have taken aspirin without untoward effect and are likely to distrust an advisor who counsels them that the ingestion of aspirin would have catastrophic effects.

TABLE 45-6 DRUGS THAT CAN PROBABLY SAFELY BE GIVEN IN NORMAL THERAPEUTIC DOSES TO G-6-PD DEFICIENT SUBJECTS WITHOUT NONSPHEROCYTIC HEMOLYTIC ANEMIA*

In the A– type of G-6-PD deficiency the hemolytic anemia is self-limited150 because the young red cells produced in response to hemolysis have nearly normal G-6-PD levels and are relatively resistant to hemolysis.152 The hemoglobin level may return to normal even while the same dose of drug that initially precipitated hemolysis is administered. In contrast, hemolysis is not self-limited in the more severe Mediterranean type of deficiency.153
HEMOLYTIC ANEMIA OCCURRING DURING INFECTION
Anemia often develops rather suddenly in G-6-PD-deficient individuals within a few days of onset of a febrile illness. The anemia is usually relatively mild, with a decline in the hemoglobin concentration of 3 or 4 g/dl. Hemolysis has been noted particularly in patients suffering from pneumonia and in those with typhoid fever. The fulminating form of the disease occurs particularly frequently among G-6-PD-deficient patients who are infected with Rocky Mountain spotted fever.154 Jaundice is not a prominent part of the clinical picture, except where hemolysis occurs in association with infectious hepatitis.155,156 In that case it can be quite intense. Presumably because of the effect of the infection reticulocytosis is usually absent, and recovery from the anemia is generally delayed until after the active infection has abated.
DIABETIC KETOACIDOSIS
Diabetic ketoacidosis has usually been considered a cause of hemolysis in G-6-PD-deficient individuals, but a review of 36 episodes of diabetic ketoacidosis in G-6-PD-deficient subjects yielded only 10 in whom hemolysis occurred, and these all were associated with infection or drug ingestion.157 It has been suggested that hypoglycemia may precipitate hemolysis.158
FAVISM
Favism is potentially one of the gravest clinical consequences of G-6-PD deficiency. It occurs much more commonly in children than in adults and occurs almost exclusively in persons who have inherited variants of G-6-PD that cause severe deficiency, but rarely the disorder has been noted in patients with G-6-PD A–.159 The onset of hemolysis may be quite sudden, having been reported to occur within the first hours after exposure to fava beans. More commonly the onset is gradual, hemolysis being noticed 1 to 2 days after ingestion of the beans.160 The urine becomes red or quite dark, and in severe cases shock may develop within a short time. Occasionally ingestion of other foodstuffs, such as unripe peaches161 or a spiced Nigerian barbecued meat known as red suya,162 has been reported to precipitate hemolysis.
NEONATAL ICTERUS
Icterus neonatorum without evidence of immunologic incompatibility occurs in some infants with G-6-PD deficiency.163 The jaundice may be quite severe and if untreated may result in kernicterus. Thus, G-6-PD deficiency is a preventable cause of mental retardation,164,165 and this aspect of the disorder has considerable public health significance.
EFFECTS ON OTHER TISSUES
In the common variants of G-6-PD such as G-6-PD A– and G-6-PD Mediterranean, and even in most of the severely deficient variants, there is usually no demonstrated defect in leukocyte number or function.166 However, there have been reports of isolated instances of leukocyte dysfunction associated with rare, severely deficient variants of G-6-PD.167,168 and 169 Patients with G-6-PD deficiency do not have a bleeding tendency, and studies of platelet function have yielded conflicting results.170,171 Occasionally, cataracts have been observed in patients with variants of G-6-PD that produce nonspherocytic hemolytic anemia.172,173 and 174 The incidence of senile cataracts may be increased in G-6-PD deficiency,175,176 but this remains controversial.177 Although claims have been made that an association exists between various kinds of G-6-PD deficiency and cancer178,179 the data are not convincing, and a detailed investigation of hematologic malignancies in patients with G-6-PD Mediterranean shows no effect.180 Decrease in insulin release181 and in cortisol levels after ACTH stimulation182 have been reported to occur in G-6-PD-deficient men.
HEREDITARY NONSPHEROCYTIC HEMOLYTIC ANEMIA
Most patients with hereditary nonspherocytic hemolytic anemia manifest only the usual clinical signs and symptoms of chronic hemolysis. The degree of anemia in this group of disorders varies widely. In some cases of very severe pyruvate kinase deficiency scarcely any deficient cells survive in the circulation and only transfused cells are found, or steady-state hemoglobin levels as low as 5 g/dl may be encountered. Other patients with hereditary nonspherocytic hemolytic anemia may manifest compensated hemolysis with a normal steady-state hemoglobin concentration. Chronic jaundice is a common finding and splenomegaly is often present. Gallstones are common. As in other forms of chronic hemolytic anemia, ankle ulcers may be present.183,184 Pregnancy has been thought to precipitate hemolysis in patients with pyruvate kinase deficiency, perhaps even in heterozygotes.185,186
In the case of some enzyme defects, characteristic nonhematologic systemic manifestations may be present, and these may be the only sign of the enzyme deficiency. For example, patients with phosphofructokinase deficiency may have type VII muscle glycogen storage disease. In some with this defect hemolysis is present without muscle manifestations, but in others both muscle abnormalities and hemolysis occur.187 Glutathione synthetase deficiency may be associated with 5-oxoprolinuria and neuromuscular disturbances, and such abnormalities may occur either with188 or without17 hematologic abnormalities. On the other hand, some patients with glutathione synthetase deficiency manifest only the hematologic abnormalities.60 Spinocerebellar degeneration was documented in the first case of g-glutamylcysteine synthetase described189,190 but was not present in subsequently investigated patients.60,191 Patients with TPI deficiency nearly always manifest serious neuromuscular disease, and most of the patients who inherit this abnormality die in the first decade of life192,193 and 194 but there are exceptions, since only one of two brothers with the same genotype manifested neurologic disease.195,196 Neurologic symptoms have also been noted in a patient with glucosephosphate isomerase deficiency.197 This enzyme seems to be identical to neuroleukin, which could explain the existence of neurologic manifestations. Myoglobinuria has been encountered in patients with phosphoglycerate kinase,16,198 aldolase,199 and G-6-PD deficiency.200 The clinical features of enzyme deficiencies causing nonspherocytic hemolytic anemia are summarized in Table 45-1.
LABORATORY FEATURES
In the absence of hemolysis, the light-microscopic morphology of G-6-PD-deficient red cells appears to be normal. Differences in the texture of the stroma of the cells have, however, been observed under the electron microscope.201
Varying degrees of anemia and reticulocytosis are the main routine hematologic laboratory features of patients with hereditary nonspherocytic hemolytic anemia. Heinz bodies often are found in the erythrocytes of G-6-PD-deficient patients undergoing drug-induced hemolysis and in splenectomized but not in unsplenectomized patients with unstable hemoglobins. When a hemolytic drug is administered to a G-6-PD-deficient patient, Heinz bodies (see Chap. 22) develop in the erythrocytes immediately preceding and in the early phases of the hemolytic episode. If the hemolytic anemia is very severe, spherocytosis and red cell fragmentation may be seen in the stained film. Although “bite cells” have been noted in the blood of a G-6-PD-deficient patient undergoing drug-induced hemolysis,202 such cells have also been noted in nondeficient patients.203,204
The presence of small, densely staining cells has often been noted in the blood films of patients with hereditary nonspherocytic hemolytic anemia with defects other than G-6-PD deficiency. Particularly when manifesting an echinocytic appearance, such cells have been thought to be common in pyruvate kinase deficiency. In one reported case205 spectacular numbers of such cells were observed. However, cells of this type are seen in many blood films both from patients with glycolytic enzyme deficiencies and from those with other disorders, and it is hazardous to attempt to make an enzymatic diagnosis on the basis of such findings. Basophilic stippling of the erythrocytes is prominent in most patients with pyrimidine-5′-nucleotidase deficiency but may not be apparent in blood that has been collected in EDTA anticoagulant. Leukopenia occasionally is observed in patients with hereditary nonspherocytic hemolytic anemia, possibly secondary to splenic enlargement. Other laboratory stigmata of increased hemolysis may include increased levels of serum bilirubin, decreased haptoglobin levels, and increased serum lactic dehydrogenase activity.
Diagnosis of red cell enzyme deficiencies depends on the demonstration of decreased enzyme activity through either a quantitative assay or a screening test.113,206,207 and 208 Assay of most of the enzymes generally is carried out by measuring the rate of reduction or oxidation of nicotinamide adenine nucleotides in an ultraviolet spectrophotometer, and a number of screening tests that depend upon the development or loss of fluorescence have been devised.206
Although detection of G-6-PD deficiency in the healthy, fully affected (hemizygous) male can be achieved readily through either assay or screening tests, difficulties arise when a patient with G-6-PD deficiency of the A– type has undergone a hemolytic episode. As the older, more enzyme-deficient cells are removed from the circulation and are replaced by young cells, the level of the enzyme begins to increase toward normal. Under such circumstances, suspicion that the patient may be G-6-PD deficient should be raised by the fact that enzyme activity is not increased even though the reticulocyte count is elevated. Centrifugation of the blood followed by testing of the most dense, reticulocyte-depleted red cells has been employed as a means for the detection of G-6-PD deficiency in persons with the A– defect who have recently undergone hemolysis.209,210 It is helpful to carry out family studies or to wait until the circulating red cells have aged sufficiently to betray their lack of enzyme.
Even greater difficulties are encountered in attempting to diagnose heterozygotes for G-6-PD deficiency.211 Because the gene is X-linked, a population of normal red cells coexists with the deficient cells (see Chap. 9). This may mask the enzyme deficiency when screening tests are used. Even enzyme assays carried out on erythrocytes of heterozygous females frequently may be in the normal range. Here methods that depend upon histochemical demonstration of individual red cell enzyme activity may be useful.212,213 In addition, the ascorbate-cyanide test,214 in which screening is carried out on a whole-cell population rather than on a lysate, may be more sensitive than the other screening procedures. However, when the nucleotide substitution is known, heterozygotes are easily detected by PCR-based analysis of the mutation.215 Prenatal diagnosis of G-6-PD deficiency is also possible using this approach.216
Identifying specific G-6-PD variants on the basis of biochemical variations requires the use of relatively sophisticated techniques. The enzyme must be partially purified, and then its Km for NADP+ and glucose-6-phosphate, its utilization of substrate analogs, its pH optima, and its electrophoretic mobility must be determined in standard systems.77 At best there is often uncertainty regarding minor differences in the characteristics of enzymes studied in this way. Detailed biochemical characterization of G-6-PD variants has therefore largely been replaced by PCR-based DNA analysis.217,218
DIFFERENTIAL DIAGNOSIS
Drug-induced hemolytic anemia due to G-6-PD deficiency is similar in its clinical features and in certain laboratory features to drug-induced hemolytic anemia associated with unstable hemoglobins (see Chap. 48). Other enzyme defects affecting the pentose-phosphate shunt, such as a deficiency of GSH synthetase, also may mimic G-6-PD deficiency. The diagnosis of hemoglobinopathies can be excluded by performing a hemoglobin stability test and electrophoresis. Both of these are normal in G-6-PD deficiency. Some of the screening tests, particularly the ascorbate-cyanide test,214 may give positive results in the above-named disorders, but a G-6-PD assay or the fluorescent screening test will be positive only in G-6-PD deficiency.
Physicians often attempt to establish the cause of hereditary nonspherocytic hemolytic anemia on the basis of the appearance of red cells on a blood film and the results of the autohemolysis test. In reality, red cell morphology is helpful only in the diagnosis of pyrimidine-5′-nucleotidase deficiency, because of the characteristic stippling of the red cells that is observed in that disorder. After splenectomy, the appearance of Heinz bodies suggests the possible presence of an unstable hemoglobin. Autohemolysis tests provide no diagnostic information of value, except occasionally in the confirmation of the presence of hereditary spherocytosis.219
Since the laboratory diagnosis of these disorders may entail considerable expenditure of time and effort, it is prudent to perform the simplest tests for the most common causes of hereditary nonspherocytic hemolytic anemia first. Accordingly, it is useful to carry out screening tests206,207 for G-6-PD and PK activity and an isopropanol stability test220 to detect an unstable hemoglobin. The characteristically elevated levels of red cell 2,3-bisphosphoglycerate and of 3-phosphoglyceric acid221 are also helpful in the diagnosis of PK deficiency. If the levels of these intermediates are normal it is extremely unlikely that the patient has PK deficiency. If prominent stippling of erythrocytes is present, examination of the ultraviolet spectrum of a perchloric acid extract of the erythrocytes may help to establish the diagnosis of pyrimidine-5′-nucleotidase deficiency.222 Beyond these relatively simple procedures it is probably rarely profitable to pick and choose individual enzyme assays on the basis of family history or clinical manifestations. Rather, it is usually appropriate to submit a blood sample to a reference laboratory that has the capability of performing all the enzyme assays listed in Table 45-1. Prenatal diagnosis of some of the defects causing hereditary nonspherocytic hemolytic anemia has been achieved,223 but diagnosis of pyruvate kinase deficiency in the unborn has not yet been achieved.
The estimation of the red cell membrane lipid composition and the study of membrane proteins usually are carried out only in research laboratories.
THERAPY, COURSE, AND PROGNOSIS
THERAPY OF G-6-PD DEFICIENCY
G-6-PD-deficient individuals should avoid drugs that might induce hemolytic episodes (see Table 45-5). However, it is important to realize that such patients are able to tolerate most drugs. Unfortunately, in the 1950s and 1960s a number of case reports incorrectly suggested that some drugs had hemolytic potential that subsequently were shown to be safe. Table 45-6 lists such drugs. While it is possible that some of these may be hemolytic in some patients or under some circumstances, this is unlikely, and G-6-PD-deficient patients should not be deprived of the possible benefit of these drugs.
If hemolysis occurs as a result of drug ingestion or infection, particularly in the milder A– type of deficiency, transfusion usually is not required. If, however, the rate of hemolysis is very rapid, as may occur for example in favism, transfusions of whole blood or packed cells may be useful. Good urine flow should be maintained in patients with hemoglobinuria to avert renal damage. Infants with neonatal jaundice due to G-6-PD deficiency may require exchange transfusion; in areas in which G-6-PD deficiency is prevalent, care must be taken not to give G-6-PD-deficient blood to such newborns.224
Patients with hereditary nonspherocytic hemolytic anemia due to G-6-PD deficiency usually do not require any therapy. Splenectomy is generally ineffective, although some improvement occasionally has been reported12 following removal of the spleen. In most cases the anemia is not very severe, but in some instances frequent transfusions have been necessary.225 The anti-oxidant properties of vitamin E have been tested in G-6-PD-deficient subjects, and a slight but statistically significant reduction in hemolysis was observed.226,227 These results could not be confirmed in other studies.228,229 It has been suggested that desferrioxamine decreases hemolysis.230,231
SPLENECTOMY IN NONSPHEROCYTIC HEMOLYTIC ANEMIA
The principal decision that the physician must make regarding patients with hereditary nonspherocytic hemolytic anemia is whether or not they require a splenectomy. This decision is not made easily, since the response is not predictable and some patients who fail to respond may develop serious thrombotic complications. The recommendation that is made should be based upon the following considerations: (1) severity of the disease; (2) family history of response to splenectomy; (3) the underlying defect; and (4) the need for cholecystectomy. Since it is unusual to obtain more than a partial response to splenectomy, this procedure should probably be reserved for patients whose quality of life is impaired by their anemia. The operation needs to be particularly considered for patients who need frequent transfusion and for those who require gallbladder surgery, in which splenectomy might be carried out as part of the same procedure. The best guide to the likely efficacy of splenectomy is probably the response to splenectomy of other affected family members. Unfortunately, such information is only occasionally available. The physician must therefore rely upon the experience of other patients with hereditary nonspherocytic hemolytic anemia of similar etiology to serve as a guide. However, even as the large group of patients with hereditary nonspherocytic hemolytic anemia represents a heterogeneous population, so individuals with a single enzymatic lesion, such as pyruvate kinase deficiency, are heterogeneous. Each family is likely to be afflicted with a distinct mutant enzyme, and the various mutants may differ both with respect to clinical manifestations and with respect to response to splenectomy. Some of the available information regarding response to splenectomy of patients with hereditary nonspherocytic hemolytic anemia has been reviewed12 and is summarized in Table 45-1. Relatively little is known of the response of patients with unstable hemoglobins to splenectomy (see Chap. 48).
GLUCOCORTICOIDS
Glucocorticoids are of no known value in this group of disorders. Folic acid is often given, as in other patients with increased bone marrow activity, but without proven hematologic benefit. In the absence of iron deficiency, iron is contraindicated. Iron overload is not a frequent complication in this group of disorders but has been reported to occur, particularly in connection with pyruvate kinase deficiency.232
COURSE AND PROGNOSIS
Hemolytic episodes in the A– type of deficiency are usually self-limited, even if drug administration is continued. This is not the case in the more severe Mediterranean type of deficiency. In patients with hereditary nonspherocytic hemolytic anemia due to G-6-PD deficiency, gallstones may occur, and the incidence of cholelithiasis may be increased even in patients with polymorphic forms of G-6-PD deficiency in Sardinia.233 During periods of infections or drug administration, anemia may increase in severity. Otherwise, the hemoglobin level of affected subjects remains relatively stable.
Nearly all patients with drug- or infection-induced hemolysis recover uneventfully. Favism must be considered, by comparison, a relatively dangerous disease. Prior to the institution of modern hospital therapy, fatalities from favism were not uncommon.
In one large population study, a decreasing incidence of G-6-PD deficiency was noted with increasing age of the population,234 but no such change was observed in another.133 While age stratification might represent evidence of a shorter life span for individuals with the A– deficiency, other factors are more likely explanations. Examination of the health records of over 65,000 U.S. Veterans Administration males failed to reveal any higher frequency of any illness in G-6-PD-deficient compared to nondeficient subjects.123 In view of the benign nature of the common types of G-6-PD deficiency, community-based population screening is not recommended. However, screening for G-6-PD deficiency of all patients admitted to the hospital may be useful in anticipating hemolytic reactions and in understanding them if they occur. This is particularly prudent if a drug such as dapsone, known to cause hemolysis in G-6-PD-deficient individuals, is to be given. Study of family members of patients with this X-linked enzyme deficiency can be helpful in providing appropriate counseling to affected individuals.
The diagnosis of hereditary nonspherocytic hemolytic anemia has been made as late as the seventh decade,13 and the disease can be fatal in the first few years of life. Triosephosphate isomerase deficiency appears to have the worst prognosis of all of the known defects that cause this disorder. With few exceptions, patients with this deficiency have died by the fifth or sixth year of life, usually of cardiopulmonary failure. Pyruvate kinase deficiency, too, can be fatal in early childhood; the gene prevalent among the Amish of Pennsylvania produces particularly severe disease.235 Unless the affected homozygous children have their spleens removed, the disorder is commonly lethal. In general, however, hereditary nonspherocytic hemolytic anemia is a relatively mild disease and most affected individuals lead a relatively normal life, apparently without much compromise of life span.
CHAPTER REFERENCES

1.
Beutler E: The hemolytic effect of primaquine and related compounds. A review. Blood 14:103, 1959.

2.
Beutler E: G6PD deficiency. Blood 84:3613, 1994.

3.
Beutler E: The study of glucose-6-phosphate dehydrogenase: History and molecular biology. Am J Hematol 42:53, 1993.

4.
Crosby WA: Hereditary nonspherocytic hemolytic anemia. Blood 5:233, 1950.

5.
Dacie JV: The congenital anaemias, in The Haemolytic Anaemias, p 171. Grune & Stratton, New York, 1960.

6.
Newton WA Jr, Bass JC: Glutathione sensitive chronic non-spherocytic hemolytic anemia. Am J Dis Child 96:501, 1958.

7.
Selwyn JG, Dacie JV: Autohemolysis and other changes resulting from the incubation in vitro of red cells from patients with congenital hemolytic anemia. Blood 9:414, 1954.

8.
Robinson MA, Loder PB, DeGruchy GC: Red-cell metabolism in non-spherocytic congenital haemolytic anaemia. Br J Haematol 7:327, 1961.

9.
DeGruchy GC, Santamaria JN, Parsons IC, Crawford H: Nonspherocytic congenital hemolytic anemia. Blood 16:1371, 1960.

10.
Valentine WN, Tanaka KR, Miwa S: A specific erythrocyte glycolytic enzyme defect (pyruvate kinase) in three subjects with congenital non-spherocytic hemolytic anemia. Trans Assoc Am Physicians 74:100, 1961.

11.
Dacie JV: Life and death of the red cell, in Blood Pure and Eloquent, p 211. McGraw-Hill, New York, 1980.

12.
Beutler E: Hemolytic Anemia in Disorders of Red Cell Metabolism. Plenum Press, New York, 1978.

13.
Beutler E: Red cell enzyme defects as non-diseases and as diseases. Blood 54:1, 1979.

14.
Shinohara K, Tanaka KR: Hereditary deficiency of erythrocyte acetylcholinesterase. Am J Hematol 7:313, 1979.

15.
Wakabayashi H, Tsuchiya M, Yoshino K, Kaku K, Shigei H: Hereditary deficiency of lactate dehydrogenase H-subunit. Intern Med 35:550, 1996.

16.
Rosa R, George C, Fardeau M, et al: A new case of phosphoglycerate kinase deficiency: PGK Creteil associated with rhabdomyolysis and lacking hemolytic anemia. Blood 60:84, 1982.

17.
Marstein S, Jellum E, Halpern B, Eldjarn L, Perry TL: Biochemical studies of erythrocytes in a patient with pyroglutamic acidemia (5-oxoprolinemia). N Engl J Med 295:406, 1976.

18.
Loos H, Roos D, Weening R, Houwerzijl J: Familial deficiency of glutathione reductase in human blood cells. Blood 48:53, 1976.

19.
Beutler E, Kuhl W, Gelbart T: 6-Phosphogluconolactonase deficiency, a hereditary erythrocyte enzyme deficiency: Possible interaction with glucose-6-phosphate dehydrogenase deficiency. Proc Natl Acad Sci USA 82:3876, 1985.

20.
Boulard-Heitzmann P, Boulard M, Tallineau C, et al: Decreased red cell enolase activity in a 40-year-old woman with compensated haemolysis. Scand J Haematol 33:401, 1984.

21.
Beutler E, Dunning D, Dabe IB, Forman L: Erythrocyte glutathione S-transferase deficiency and hemolytic anemia. Blood 72:73, 1988.

22.
Beutler E, Carson D, Dannawi H, et al: Metabolic compensation for profound erythrocyte adenylate kinase deficiency. J Clin Invest 72:648, 1983.

23.
Shohet SB, Livermore BM, Nathan DG, Jaffe ER: Hereditary hemolytic anemia associated with abnormal membrane lipids: Mechanism of accumulation of phosphatidyl choline. Blood 38:445, 1971.

24.
Lane PA, Kuypers FA, Clark MR, et al: Excess of red cell membrane proteins in hereditary high-phosphatidylcholine hemolytic anemia. Am J Hematol 34:186, 1990.

25.
Shojania AM, Godin DV, Frohlich J: Hereditary high phosphatidylcholine hemolytic anemia: Report of a new family and review of the literature. Clin Invest Med 13:313, 1990.

26.
Clark MR, Shohet SB, Gottfried EL: Hereditary hemolytic disease with increased red blood cell phosphatidylcholine and dehydration: One, two, or many disorders. Am J Hematol 42:25, 1993.

27.
Dern RJ, Beutler E, Alving AS: The hemolytic effect of primaquine: V. Primaquine sensitivity as a manifestation of a multiple drug sensitivity. J Lab Clin Med 45:30, 1955.

28.
Cohen G, Hochstein P: Generation of hydrogen peroxide in erythrocytes by hemolytic agents. Biochemistry 3:895, 1964.

29.
Kosower NS, Song KR, Kosower EM, Correa W: Glutathione: II. Chemical aspects of azoester procedure for oxidation to disulfide. Biochim Biophys Acta 192:8, 1969.

30.
Birchmeier W, Tuchschmid PE, Winterhalter H: Comparison of human hemoglobin A carrying glutathione as a mixed disulfide with the naturally occurring human hemoglobin A3. Biochemistry 12:3667, 1973.

31.
Rachmilewitz EA, Harari E, Winterhalter KH: Separation of alpha- and beta-chains of hemoglobin A by acetylphenylhydrazine. Biochim Biophys Acta 371:402, 1974.

32.
Itano HA, Hosokawa K, Hirota K: Induction of haemolytic anaemia by substituted phenylhydrazines. Br J Haematol 32:99, 1976.

33.
Srivastava SK, Beutler E: Glutathione metabolism of the erythrocyte. The enzymic cleavage of glutathione-haemoglobin preparations by glutathione reductase. Biochem J 119:353, 1970.

34.
Kirkman HN, Gaetani GF: Catalase: A tetrameric enzyme with four tightly bound molecules of NADPH. Proc Natl Acad Sci USA 81:4343, 1984.

35.
Gaetani GF, Rolfo M, Arena S, et al: Active involvement of catalase during hemolytic crises of favism. Blood 88:1084, 1996.

36.
Rifkind RA: Heinz body anemia: An ultrastructural study: II. Red cell sequestration and destruction. Blood 26:433, 1965.

37.
Bunn HEF, Jandl JH: Exchange of heme among hemoglobin molecules. Proc Natl Acad Sci USA 56:974, 1966.

38.
Jandl JH: The Heinz body hemolytic anemias. Ann Intern Med 58:702, 1963.

39.
Beutler E: Abnormalities of glycolysis (HMP shunt). Bibl Haematol 29:146, 1968.

40.
Baehner RL, Nathan DG, Castle WB: Oxidant injury of caucasian glucose-6-phosphate dehydrogenase-deficient red blood cells by phagocytosing leukocytes during infection. J Clin Invest 50:2466, 1971.

41.
Arese P, De Flora A: Denaturation of normal and abnormal erythrocytes: II. Pathophysiology of hemolysis in glucose-6-phosphate dehydrogenase deficiency. Semin Hematol 27:1, 1990.

42.
Stamatoyannopoulos G, Fraser GR, Motulsky AG, et al: On the familial predisposition to favism. Am J Hum Genet 18:253, 1966.

43.
Cassimos CHR, Malaka-Zafiriu K, Tsiures J: Urinary D-glucaric acid excretion in normal and G-6-PD deficient children with favism. J Pediatr 84:871, 1974.

44.
Bottini E, Bottini FG, Borgiani P, Businco L: Association between ACP1 and favism: a possible biochemical mechanism. Blood 89:2613, 1997.

45.
Fiorelli G, Podda M, Corrias A, Fargion S: The relevance of immune reactions in acute favism. Acta Haematol (Basel) 51:211, 1974.

46.
Turrini F, Naitana A, Mannuzzu L, Pescarmona G, Arese P: Increased red cell calcium, decreased calcium adenosine triphosphatase, and altered membrane proteins during fava bean hemolysis in glucose-6-phosphate dehydrogenase-deficient (Mediterranean variant) individuals. Blood 66:302, 1985.

47.
De Flora A, Benatti U, Guida L, Forteleoni G, Meloni T: Favism: Disordered erythrocyte calcium homeostasis. Blood 66:294, 1985.

48.
Fischer TM, Meloni T, Pescarmona GP, Arese P: Membrane cross bonding in red cells in favic crisis: A missing link in the mechanism of extravascular haemolysis. Br J Haematol 59:159, 1985.

49.
Kaplan M, Vreman HJ, Hammerman C, et al: Contribution of haemolysis to jaundice in Sephardic Jewish glucose-6-phosphate dehydrogenase deficient neonates. Br J Haematol 93:822, 1996.

50.
Kaplan M, Renbaum P, Levy-Lahad E, et al: Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: A dose-dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci USA 94:12128, 1997.

51.
Oluboyede OA, Esan GJF, Francis TI, Luzzatto L: Genetically determined deficiency of glucose 6-phosphate dehydrogenase (type A–) is expressed in the liver. J Lab Clin Med 93:783, 1979.

52.
Piomelli S: G6PD deficiency and hemolytic anemia: G6PD-related neonatal jaundice, in Glucose-6-Phosphate Dehydrogenase, p 95. Academic Press, Orlando, FL, 1986.

53.
Ifekwunigwe AE, Luzzatto L: Kernicterus in G.-6-P.D.-deficiency. Lancet 1:667, 1966.

54.
Eshaghpour E, Oski FA, Williams M: The relationship of erythrocyte glucose-6-phosphate dehydrogenase deficiency to hyperbilirubinemia in Negro premature infants. J Pediatr 70:595, 1967.

55.
Lopez R, Cooperman JM: Glucose-6-phosphate dehydrogenase deficiency and hyperbilirubinemia in the newborn. Am J Dis Child 122:66, 1971.

56.
Zinkham WH: Peripheral blood and bilirubin values in normal full-term primaquine-sensitive negro infants: Effect of vitamin K. Pediatrics 31:983, 1963.

57.
Verdy E, Herve J, Boisson C, Combrisson A: Can glucose-6-phosphate dehydrogenase deficiency alone explain neonatal jaundice. Rev Fr Transfus Immunohematol 21:1081, 1978.

58.
Beutler E, Gelbart T, Demina A: Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: A balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170, 1998.

59.
Dahl N, Pigg M, Ristoff E, et al: Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction. Hum Mol Genet 6:1147, 1997.

60.
Hirono A, Iyori H, Sekine I, et al: Three cases of hereditary nonspherocytic hemolytic anemia associated with red blood cell glutathione deficiency. Blood 87:2071, 1996.

61.
Beutler E, Gelbart T, Pegelow C: Erythrocyte glutathione synthetase deficiency leads not only to glutathione but also to glutathione-S-transferase deficiency. J Clin Invest 77:38, 1986.

62.
Parr CW, Fitch LI: Inherited quantitative variations of human phosphogluconate dehydrogenase. Ann Hum Genet 30:339, 1967.

63.
Valentine WN, Paglia DE: The primary cause of hemolysis in enzymopathies of anaerobic glycolysis: A viewpoint. Blood Cells 6:819, 1980.

64.
Beutler E: “The primary cause of hemolysis in enzymopathies of anaerobic glycolysis: A viewpoint.” A commentary. Blood Cells 6:827, 1980.

65.
Werth G, Mueller G: Vererbbarer Glucose-6-phosphatdehydrogenasemangel in den Erythrocyten von Ratten. Klin Wochenschr 45:265, 1967.

66.
Smith JE, Ryer K, Wallace L: Glucose-6-phosphate dehydrogenase deficiency in a dog. Enzyme 21:379, 1976.

67.
Pretsch W, Charles DJ, Merkle S: X-linked glucose-6-phosphate dehydrogenase deficiency in Mus musculus. Biochem Genet 26:89, 1988.

68.
Sanders S, Smith DP, Thomas GA, Williams ED: A glucose-6-phosphate dehydrogenase (G6PD) splice site consensus sequence mutation associated with G6PD enzyme deficiency. Mutat Res 374:79, 1997.

69.
Nonneman D, Stockham SL, Shibuya H, Messer NTI, Johnson GS: A missense mutation in the glucose-6-phosphate dehydrogenase gene associated with hemolytic anemia in an American saddlebred horse. Blood 82 (suppl 1):466a, 1993.

70.
Stockham SL, Harvey JW, Kinden DA: Equine glucose-6-phosphate dehydrogenase deficiency. Vet Pathol 31:518, 1994.

71.
Whitney KM, Goodman SA, Bailey EM, Lothrop CD Jr: The molecular basis of canine pyruvate kinase deficiency. Exp Hematol 22:866, 1994.

72.
Kanno H, Morimoto M, Fujii H, et al: Primary structure of murine red blood cell-type pyruvate kinase (PK) and molecular characterization of PK deficiency identified in the CBA strain. Blood 86:3205, 1995.

73.
Morimoto M, Kanno H, Asai H, et al: Pyruvate kinase deficiency of mice associated with nonspherocytic hemolytic anemia and cure of the anemia by marrow transplantation without host irradiation. Blood 86:4323, 1995.

74.
Tsujino K, Kanno H, Hashimoto K, et al: Delayed onset of hemolytic anemia in CBA-Pk-1slc/Pk-1slc mice with a point mutation of the gene encoding red blood cell type pyruvate kinase. Blood 91:2169, 1998.

75.
Harvey JW, Pate MG, Mhaskar Y, Dunaway GA: Characterization of phosphofructokinase-deficient canine erythrocytes. J Inherit Metab Dis 15:747, 1992.

76.
Merkle S, Pretsch W: Glucose-6-phosphate isomerase deficiency associated with nonspherocytic hemolytic anemia in the mouse: An animal model for the human disease. Blood 81:206, 1993.

77.
Betke K, Beutler E, Brewer GJ, et al: Standardization of procedures for the study of glucose-6-phosphate dehydrogenase. Report of a WHO scientific group. WHO Tech Rep Ser No. 366:1967.

78.
Piomelli S, Corash LM, Davenport DD, Miraglia J, Amorosi EL: In vivo lability of glucose-6-phosphate dehydrogenase in GdA– and Gd Mediterranean deficiency. J Clin Invest 47:940, 1968.

79.
Yoshida A, Stamatoyannopoulos G, Motulsky A: Negro variant of glucose-6-phosphate dehydrogenase deficiency (A–) in man. Science 155:97, 1967.

80.
Kahn A, Cottreau D, Boivin P: Molecular mechanism of glucose-6-phosphate dehydrogenase deficiency. Humangenetik 25:101, 1974.

81.
Beutler E: Selectivity of proteases as a basis for tissue distribution of enzymes in hereditary deficiencies. Proc Natl Acad Sci USA 80:3767, 1983.

82.
Kirkman HN, Schettini F, Pickard BM: Mediterranean variant of glucose-6-phosphate dehydrogenase. J Lab Clin Med 63:726, 1964.

83.
Kirkman HN, Riley HD Jr: Congenital nonspherocytic hemolytic anemia. Am J Dis Child 102:313, 1961.

84.
Yoshida A: Hemolytic anemia and G-6-PD deficiency. Science 179:532, 1973.

85.
Beutler E: Genetics of glucose-6-phosphate dehydrogenase deficiency. Semin Hematol 27:137, 1990.

86.
Chen EY, Cheng A, Lee A, et al: Sequence of human glucose-6-phosphate dehydrogenase cloned in plasmids and a yeast artificial chromosome (YAC). Genomics 10:792, 1991.

87.
Battistuzzi G, D’Urso M, Toniolo D, Persico GM, Luzzatto L: Tissue-specific levels of human glucose-6-phosphate dehydrogenase correlate with methylation of specific sites at the 3′ end of the gene. Proc Natl Acad Sci USA 82:1465, 1985.

88.
Kirkman HN, Hendrickson EM: Glucose-6-phosphate dehydrogenase from human erythrocytes: II. Subactive states of the enzyme from normal persons. J Biol Chem 237:2371, 1962.

89.
De Flora A, Morelli A, Giuliano F: Human erythrocyte glucose 6-phosphate dehydrogenase. Content of bound coenzyme. Biochem Biophys Res Commun 59:406, 1974.

90.
De Flora A, Morelli A, Benatti U, Giuliano F, Molinari MP: Human erythrocyte glucose 6-phosphate dehydrogenase. Interaction with oxidized and reduced coenzyme. Biochem Biophys Res Commun 60:999, 1974.

91.
Canepa L, Ferraris AM, Miglino M, Gaetani GF: Bound and unbound pyridine dinucleotides in normal and glucose-6-phosphate dehydrogenase-deficient erythrocytes. Biochim Biophys Acta 1074:101, 1991.

92.
Camardella L, Caruso C, Rutigliano B, et al: Human erythrocyte glucose-6-phosphate dehydrogenase: Identification of a reactive lysyl residue labelled with pyridoxal 5′-phosphate. Eur J Biochem 171:485, 1988.

93.
Jeffery J, Wood I, Macleod A, Jeffrey R, Jörnvall A: Glucose-6-phosphate dehydrogenase. Characterization of a reactive lysine residue in the Pichia jadinii enzyme reveals a limited structural variation in a functionally significant segment. Biochem Biophys Res Commun 160:1290, 1989.

94.
Hirono A, Kuhl W, Gelbart T, et al: Identification of the binding domain for NADP+ of human glucose-6-phosphate dehydrogenase by sequence analysis of mutants. Proc Natl Acad Sci USA 86:10015, 1989.

95.
Naylor CE, Rowland P, Basak AK, et al: Glucose-6-phosphate dehydrogenase mutations causing enzyme deficiency in a model of the tertiary structure of the human enzyme. Blood 87:2974, 1996.

96.
Yoshida A: A single amino acid substitution (asparagine to aspartic acid) between normal (B+) and the common negro variant (A+) of human glucose-6-phosphate dehydrogenase. Proc Natl Acad Sci USA 57:835, 1967.

97.
Takizawa T, Yoneyama Y, Miwa S, Yoshida A: A single nucleotide base transition is the basis of the common human glucose-6-phosphate dehydrogenase variant A(+). Genomics 1:228, 1987.

98.
Hirono A, Beutler E: Molecular cloning and nucleotide sequence of cDNA for human glucose-6-phosphate dehydrogenase variant A(–). Proc Natl Acad Sci USA 85:3951, 1988.

99.
Town M, Bautista JM, Mason PJ, Luzzatto L: Both mutations in G6PD A– are necessary to produce the G6PD deficient phenotype. Hum Mol Genet 1:171, 1992.

100.
Beutler E, Kuhl W, Vives-Corrons J-L, Prchal JT: Molecular heterogeneity of G6PD A–. Blood 74:2550, 1989.

101.
Vulliamy TJ, Othman A, Town M, et al: Polymorphic sites in the African population detected by sequence analysis of the glucose-6-phosphate dehydrogenase gene outline the evolution of the variants A and A–. Proc Natl Acad Sci USA 88:8568, 1991.

102.
Huang C-S, Hung KL, Huang MJ, et al: Neonatal jaundice and molecular mutations in glucose-6-phosphate dehydrogenase deficient newborn infants. Am J Hematol 51:19, 1996.

103.
Xu W, Westwood B, Bartsocas CS, et al: Glucose-6 phosphate dehydrogenase mutations and haplotypes in various ethnic groups. Blood 85:257, 1995.

104.
Saha S, Saha N, Tay JSH, et al: Molecular characterisation of red cell glucose-6-phosphate dehydrogenase deficiency in Singapore Chinese. Am J Hematol 47:273, 1994.

105.
Tang TK, Huang C-S, Huang M-J, et al: Diverse point mutations result in glucose-6-phosphate dehydrogenase (G6PD) polymorphism in Taiwan. Blood 79:2135, 1992.

106.
Vulliamy T, Luzzatto L, Hirono A, Beutler E: Hematologically important mutations: Glucose-6-phosphate dehydrogenase. Blood Cells Mol Dis 23:302, 1997.

107.
MacDonald D, Town M, Mason P, et al: Deficiency in red blood cells. Nature 350:115, 1991.

108.
Baronciani L, Tricta F, Beutler E: G6PD “Campinas”: A deficient enzyme with a mutation at the far 3′ end of the gene. Hum Mutat 2:77, 1993.

109.
Miwa S: Pyruvate kinase deficiency. Acta Haematol Jpn 50:1445, 1987.

110.
Kahn A, Kaplan J-C, Dreyfus J-C: Advances in hereditary red cell enzyme anomalies. Hum Genet 50:1, 1979.

111.
Johnson ML, Jones DP, Freeman JM, Wang W: Biochemical and molecular characterization of variant pyruvate kinase enzymes and genes from three patients with red blood cell pyruvate kinase deficiency. Acta Haematol (Basel) 86:79, 1991.

112.
Beutler E, Forman L, Rios-Larrain E: Elevated pyruvate kinase activity in patients with hemolytic anemia due to red cell pyruvate kinase “deficiency.” Am J Med 83:899, 1987.

113.
Miwa S, Boivin P, Blume KG, et al: Recommended methods for the characterization of red cell pyruvate kinase variants. Br J Haematol 43:275, 1979.

114.
Lakomek M, Neubauer B, von der Lühe A, et al: Erythrocyte pyruvate kinase deficiency: Relations of residual enzyme activity, altered regulation of defective enzymes and concentrations of high-energy phosphates with the severity of clinical manifestation. Eur J Haematol 49:82, 1992.

115.
Tani K, Fujii H, Nagata S, Miwa S: Human liver type pyruvate kinase: complete amino acid sequence and the expression in mammalian cells. Proc Natl Acad Sci USA 85:1792, 1988.

116.
Tani K, Fujii H, Tsutsumi H, et al: Human liver type-pyruvate kinase: cDNA cloning and chromosomal assignment. Biochem Biophys Res Commun 143:431, 1987.

117.
Baronciani L, Bianchi P, Zanella A: Hematologically important mutations: Red cell pyruvate kinase. Blood Cells Mol Dis 22:85, 1996.

118.
Beutler E, Baronciani L: Mutation update: Pyruvate kinase. Hum Mutat 7:1, 1996.

119.
Baronciani L, Beutler E: Molecular study of pyruvate kinase deficient patients with hereditary nonspherocytic hemolytic anemia. J Clin Invest 95:1702, 1995.

120.
Lenzner C, Nürnberg P, Jacobasch G, Gorth C, Thiele BJ: Molecular analysis of 29 pyruvate kinase-deficient patients from Central Europe with hereditary hemolytic anemia. Blood 89:1793, 1997.

121.
Baronciani L, Beutler E: Analysis of pyruvate kinase-deficiency mutations that produce nonspherocytic hemolytic anemia. Proc Natl Acad Sci USA 90:4324, 1993.

122.
Demina A, Varughese KI, Barbot J, Forman L, Beutler E: Six previously undescribed pyruvate kinase mutations causing enzyme deficiency. Blood 92:647, 1998.

123.
Heller P, Best WR, Nelson RB, Becktel J: Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med 300:1001, 1979.

124.
Luzzatto L, Battistuzzi G: Glucose-6-phosphate dehydrogenase, in Advances in Human Genetics, p 217. Plenum, New York, 1985.

125.
Luzzatto L, Mehta A: Glucose 6-phosphate dehydrogenase deficiency, in The Metabolic and Molecular Bases of Inherited Disease, 7th ed, p 3367. McGraw-Hill, New York, 1995.

126.
Motulsky AG: Metabolic metamorphisms and the role of infectious diseases in human evolution. Hum Biol 32:28, 1960.

127.
Luzzatto L, Usanga EA, Reddy S: Glucose 6-phosphate dehydrogenase deficient red cells: Resistance to infection by malarial parasites. Science 164:839, 1969.

128.
Cappadoro M, Giribaldi G, O’Brien E, et al: Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 92:2527, 1998.

129.
Piomelli S, Reindorf CA, Arzanian MT, Corash LM: Clinical and biochemical interactions of glucose-6-phosphate dehydrogenase deficiency and sickle-cell anemia. N Engl J Med 287:213, 1972.

130.
Lewis RA, Hathorn M: Correlation of S hemoglobin with glucose-6-phosphate dehydrogenase deficiency and its significance. Blood 26:176, 1965.

131.
Steinberg MH, Dreiling BJ: Glucose-6-phosphate dehydrogenase deficiency in sickle cell anemia. Ann Intern Med 80:217, 1974.

132.
Beutler E, Johnson C, Powars D, West C: Prevalence of glucose-6-phosphate dehydrogenase deficiency in sickle cell disease. N Engl J Med 290:826, 1974.

133.
Steinberg MH, West MS, Gallagher D, Mentzer WC Jr, and the Cooperative Study of Sickle Cell Diseases: Effects of glucose-6-phosphate dehydrogenase deficiency upon sickle cell anemia. Blood 71:748, 1988.

134.
Warsy AS: Frequency of glucose-6-phosphate dehydrogenase deficiency in sickle-cell disease. Hum Hered 35:143, 1985.

135.
Garcia SC, Moragon AC, Lopez-Fernandez ME: Frequency of glutathione reductase, pyruvate kinase and glucose-6-phosphate dehydrogenase deficiency in a Spanish population. Hum Hered 29:310, 1979.

136.
Abu-Melha AM, Ahmed MAM, Knox-Macaulay H, AL Sowayan SA, EL Yahia A: Erythrocyte pyruvate kinase deficiency in newborns of Eastern Saudi Arabia. Acta Haematol (Basel) 85:192, 1991.

137.
Mohrenweiser HA: Functional hemizygosity in the human genome: direct estimate from twelve erythrocyte enzyme loci. Hum Genet 77:241, 1987.

138.
Mohrenweiser HW, Fielek S: Elevated frequency of carriers for triosephosphate isomerase deficiency in newborn infants. Pediatr Res 16:960, 1982.

139.
Watanabe M, Zingg BC, Mohrenweiser HA: Molecular analysis of a series of alleles in humans with reduced activity at the triosephosphate isomerase locus. Am J Hum Genet 58:308, 1996.

140.
Schneider A, Forman L, Westwood B, et al: The relationship of the -5, -8, and -24 mutations in African-Americans to triosephosphate isomerase (TPI) enzyme activity and to TPI deficiency. Blood 92:2959, 1998.

141.
Schneider A, Westwood B, Yim C, et al: The 1591C mutation in triosephosphate isomerase (TPI) deficiency. Tightly linked polymorphisms and a common haplotype in all known families. Blood Cells Mol Dis 22:115, 1996.

142.
McCaffrey RP, Halsted CH, Wahab MFA, Robertson RP: Chloramphenicol-induced hemolysis in caucasian glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 74:722, 1971.

143.
Chan TK, Chesterman CN, McFadzean AJS, Todd D: The survival of glucose-6-phosphate dehydrogenase-deficient erythrocytes in patients with typhoid fever on chloramphenicol therapy. J Lab Clin Med 77:177, 1971.

144.
Rees DC, Kelsey H, Richards JDM: Lesson of the week: Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 306:841, 1993.

145.
Mehta JB, Singhal SB, Mehta BC: Ascorbic-acid-induced haemolysis in G-6-PD deficiency. Lancet 336:944, 1990.

146.
Campbell GD Jr, Steinberg MH, Bower JO: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med 82:810, 1975.

147.
Markowitz N, Saravolatz LD: Use of trimethoprim-sulfamethoxazole in a glucose-6-phosphate dehydrogenase-deficient population. Rev Infect Dis 9(suppl 2):S218, 1987.

148.
Magon AM, Leipzig RM, Zannoni VG, Brewer GJ: Interactions of glucose-6-phosphate dehydrogenase deficiency with drug acetylation and hydroxylation reactions. J Lab Clin Med 97:764, 1981.

149.
Woolhouse NM, Atu-Taylor LC: Influence of double genetic polymorphism on response to sulfamethazine. Clin Pharmacol Ther 31:377, 1982.

150.
Dern RJ, Beutler E, Alving AS: The hemolytic effect of primaquine: II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med 44:171, 1954.

151.
Beutler E, Dern RJ, Alving AS: The hemolytic effect of primaquine: III. A study of primaquine-sensitive erythrocytes. J Lab Clin Med 44:177, 1954.

152.
Beutler E, Dern RJ, Alving AS: The hemolytic effect of primaquine: IV. The relationship of cell age to hemolysis. J Lab Clin Med 44:439, 1954.

153.
George JN, Sears DA, McCurdy P, Conrad ME: Primaquine sensitivity in caucasians: Hemolytic reactions induced by primaquine in G-6-PD deficient subjects. J Lab Clin Med 70:80, 1967.

154.
Walker DH, Hawkins HK, Hudson P: Fulminant Rocky Mountain spotted fever. Arch Pathol Lab Med 107:121, 1983.

155.
Chau TN, Lai ST, Lai JY, Yuen H: Haemolysis complicating acute viral hepatitis in patients with normal or deficient glucose-6-phosphate dehydrogenase activity. Scand J Infect Dis 29:551, 1997.

156.
Huo TI, Wu JC, Chiu CF, Lee SD: Severe hyperbilirubinemia due to acute hepatitis A superimposed on a chronic hepatitis B carrier with glucose-6-phosphate dehydrogenase deficiency. Am J Gastroenterol 91:158, 1996.

157.
Shalev O, Wollner A, Menczel J: Diabetic ketoacidosis does not precipitate haemolysis in patients with the Mediterranean variant of glucose-6-phosphate dehydrogenase deficiency. BMJ 288:179, 1984.

158.
Shalev O, Eliakim R, Lugassy GZ, Menczel J: Hypoglycemia-induced hemolysis in glucose-6-phosphate dehydrogenase deficiency. Acta Haematol (Basel) 74:227, 1985.

159.
Galiano S, Gaetani GF, Barabino A, et al: Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A–). BMJ 300:236, 1990.

160.
Kattamis CA, Kyriazakou M, Chaidas S: Favism. Clinical and biochemical data. J Med Genet 6:34, 1969.

161.
Globerman H, Novak T, Chevion M: Haemolysis in a G6PD-deficient child induced by eating unripe peaches. Scand J Haematol 33:337, 1984.

162.
Williams CKO, Osotimehin BO, Ogunmola GB, Awotedu AA: Haemolytic anaemia associated with Nigerian barbecued meat (red suya). Afr J Med Sci 17:71, 1988.

163.
Kaplan M, Hammerman C: Severe neonatal hyperbilirubinemia. Clin Perinatol 25:575, 1998.

164.
Fok T-F, Lau S-P: Glucose-6-phosphate dehydrogenase deficiency: A preventable cause of mental retardation. BMJ 292:829, 1986.

165.
Singh A: Glucose-6-phosphate dehydrogenase deficiency: A preventable cause of mental retardation. BMJ 292:397, 1986.

166.
Ardati KO, Bajakian KM, Tabbara KS: Effect of glucose-6-phosphate dehydrogenase deficiency on neutrophil function. Acta Haematol (Basel) 97:211, 1997.

167.
Vives-Corrons JL, Feliu E, Pujades MA, et al: Severe glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction and increased susceptibility to infections. Description of a new molecular variant (G6PD Barcelona). Blood 59:428, 1982.

168.
Gray GR, Klebanoff SJ, Stamatoyannopoulos G, et al: Neutrophil dysfunction, chronic granulomatous disease, and nonspherocytic haemolytic anaemia caused by complete deficiency of glucose-6-phosphate dehydrogenase. Lancet 2:530, 1973.

169.
Cooper MR, DeChatelet LR, McCall CE, et al: Complete deficiency of leukocyte glucose-6-phosphate dehydrogenase with defective bactericidal activity. J Clin Invest 51:769, 1972.

170.
Schwartz JP, Cooperberg AA, Rosenberg A: Platelet-function studies in patients with glucose-6-phosphate dehydrogenase deficiency. Br J Haematol 27:273, 1974.

171.
Gray GR, Naiman SC, Robinson GCF: Platelet function and G-6-PD deficiency. Lancet 1:997, 1974.

172.
Harley JD, Agar NS, Yoshida A: Glucose-6-phosphate dehydrogenase variants: Gd (+) Alexandra associated with neonatal jaundice and Gd (–) Camperdown in a young man with lamellar cataracts. J Lab Clin Med 91:295, 1978.

173.
Harley JD, Agar NS, Gruca MA: Cataracts with a glucose-6-phosphate dehydrogenase variant. BMJ 2:86, 1975.

174.
Westring DW, Pisciotta AV: Anemia, cataracts, and seizures in patient with glucose-6-phosphate dehydrogenase deficiency. Arch Intern Med 118:385, 1966.

175.
Panich V, Na-Nakorn S: G6PD deficiency in senile cataracts. Hum Genet 55:123, 1980.

176.
Orzalesi N, Sorcinelli R, Guiso G: Increased incidence of cataract in male subjects deficient in glucose-6-phosphate dehydrogenase. Arch Ophthalmol 99:69, 1981.

177.
Bhatia RPS, Patel R, Dubey B: Senile cataract and glucose-6-phosphate dehydrogenase deficiency in Indians. Trop Geogr Med 42:349, 1990.

178.
Zampella EJ, Bradley EL, Pretlow TA: Glucose-6-phosphate dehydrogenase; A possible clinical indicator for prostatic carcinoma. Cancer 49:384, 1982.

179.
Sulis E: G-6-PD deficiency and cancer. Lancet 1:1185, 1972.

180.
Ferraris AM, Broccia G, Meloni T, Forteleoni G, Gaetani GF: Glucose-6-phosphate dehydrogenase deficiency and incidence of hematologic malignancy. Am J Hum Genet 42:516, 1988.

181.
Monte Alegre S, Saad STO, Delatre E, Saad MJA: Insulin secretion in patients deficient in glucose-6-phosphate dehydrogenase. Horm Metab Res 23:171, 1991.

182.
Saad MJA, Monte-Alegre S, Saad STO: Cortisol levels in glucose-6-phosphate dehydrogenase deficiency. Horm Res 35:1, 1991.

183.
Mueller-Soyano A, De Roura ET, Duke PR, et al: Pyruvate kinase deficiency and leg ulcers. Blood 47:807, 1976.

184.
Curiel CD, Velasquez GA, Papa R: Hemolytic anemia and leg ulcers due to pyruvate kinase deficiency. Report of the second Venezuelan family. Sangre (Barc) 22:64, 1977.

185.
Amankwah KS, Dick BW, Dodge S: Hemolytic anemia and pyruvate kinase deficiency in pregnancy. Obstet Gynecol 55(suppl):42S, 1980.

186.
Vives Corrons J-L, García AM, Sosa AM, et al: Heterozygous pyruvate kinase deficiency and severe hemolytic anemia in a pregnant woman with concomitant, glucose-6-phosphate dehydrogenase deficiency. Blut 62:190, 1991.

187.
Vora S: Isozymes of human phosphofructokinase: Biochemical and genetic aspects, in Isozymes: Current Topics in Biological and Medical Research, p 3. Liss, New York, 1983.

188.
Wellner VP, Sekura R, Meister A, Larsson A: Glutathione synthetase deficiency, an inborn error of metabolism involving the gamma-glutamyl cycle in patients with 5-oxoprolinuria (pyroglutamic aciduria). Proc Natl Acad Sci USA 71:2505, 1974.

189.
Konrad PN, Richards FI, Valentine WN, Paglia DE: Gamma-glutamyl-cysteine synthetase deficiency. N Engl J Med 286:557, 1972.

190.
Richards FI, Cooper MR, Pearce LA, Cowan RJ, Spurr CL: Familial spinocerebellar degeneration, hemolytic anemia, and glutathione deficiency. Arch Intern Med 134:534, 1974.

191.
Beutler E, Moroose R, Kramer L, Gelbart T, Forman L: Gamma-glutamylcysteine synthetase deficiency and hemolytic anemia. Blood 75:271, 1990.

192.
Skala H, Dreyfus JC, Vives-Corrons JL, Matsumoto F, Beutler E: Triose phosphate isomerase deficiency. Biochem Med 18:226, 1977.

193.
Valentine WN, Schneider AS, Baughan MA, Paglia DE, Heins HL Jr.: Hereditary hemolytic anemia with triosephosphate isomerase deficiency. Am J Med 41:27, 1966.

194.
Schneider AS, Valentine WN, Baughan MA, et al: Triosephosphate isomerase deficiency. A multi-system inherited enzyme disorder: Clinical and genetic aspects, in Hereditary Disorders of Erythrocyte Metabolism, p 265. Grune & Stratton, New York, 1968.

195.
Hollan S, Fujii H, Hirono A, et al: Hereditary triosephosphate isomerase (TPI) deficiency: two severely affected brothers one with and one without neurological symptoms. Hum Genet 92:486, 1993.

196.
Hollan S, Magocsi M, Fodor E, et al: Search for the pathogenesis of the differing phenotype in two compound heterozygote Hungarian brothers with the same genotypic triosephosphate isomerase deficiency. Proc Natl Acad Sci USA 94:10362, 1997.

197.
Kugler W, Breme K, Laspe P, et al: Molecular basis of neurological dysfunction coupled with haemolytic anaemia in human glucose-6-phosphate isomerase (GPI) deficiency. Hum Genet 103:450, 1998.

198.
DiMauro S, Dalakas M, Miranda AF: Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria. Ann Neurol 13:11, 1983.

199.
Kreuder J, Borkhardt A, Repp R, et al: Brief report: Inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med 334:1100, 1996.

200.
Bresolin N, Bet L, Moggio M, et al: Muscle glucose-6-phosphate dehydrogenase deficiency. J Neurol 236:193, 1989.

201.
Danon D, Sheba C, Ramot B: The morphology of glucose 6 phosphate dehydrogenase deficient erythrocytes: Electron-microscopic studies. Blood 17:229, 1961.

202.
Beaupre SR, Schiffman FJ: Rush hemolysis. A ‘bite-cell’ hemolytic anemia associated with volatile liquid nitrite use. Arch Fam Med 3:545, 1994.

203.
Greenberg MS: Heinz body hemolytic anemia. Arch Intern Med 136:153, 1976.

204.
Nathan DM, Siegel AJ, Bunn HF: Acute methemoglobinemia and hemolytic anemia with phenazopyridine. Arch Intern Med 137:1636, 1977.

205.
Oski FA, Nathan DG, Sidel VW, Diamond LK: Extreme hemolysis and red-cell distortion in erythrocyte pyruvate kinase deficiency. N Engl J Med 270:1023, 1964.

206.
Beutler E: Red Cell Metabolism: A Manual of Biochemical Methods. Grune & Stratton, New York, 1984.

207.
Beutler E, Blume KG, Kaplan JC, et al: International committee for standardization in haematology: Recommended methods for red-cell enzyme analysis. Br J Haematol 35:331, 1977.

208.
Beutler E, Blume KG, Kaplan JC, et al: International committee for standardization in haematology: Recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol 43:465, 1979.

209.
Herz F, Kaplan E, Scheye ES: Diagnosis of erythrocyte glucose-6-phosphate dehydrogenase deficiency in the negro male despite hemolytic crisis. Blood 35:90, 1970.

210.
Ringelhahn B: A simple laboratory procedure for the recognition of A– (African type) G6PD deficiency in acute haemolytic crisis. Clin Chim Acta 36:272, 1972.

211.
Beutler E: X-inactivation in heterozygous G-6-PD variant females, in Glucose-6-Phosphate Dehydrogenase, p 405. Academic Press, Orlando, FL, 1986.

212.
Beutler E: G-6-PD activity of individual erythrocytes and X-chromosomal inactivation, in Biochemical Methods in Red Cell Genetics, p 95. Academic Press, New York, 1969.

213.
Vogels IMC, van Noorden CJF, Wolf BHM, et al: Cytochemical determination of heterozygous glucose-6-phosphate dehydrogenase deficiency in erythrocytes. Br J Haematol 63:402, 1986.

214.
Jacob H, Jandl JH: A simple visual screening test for G-6-PD deficiency employing ascorbate and cyanide. N Engl J Med 274:1162, 1966.

215.
Beutler E, Kuhl W, Gelbart T, Forman L: DNA sequence abnormalities of human glucose-6-phosphate dehydrogenase variants. J Biol Chem 266:4145, 1991.

216.
Beutler E, Kuhl W, Fox M, Tabsh K, Crandall BA: Prenatal diagnosis of glucose-6-P dehydrogenase (G6PD) deficiency. Acta Haematol (Basel) 87:103, 1992.

217.
Beutler E: Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Biochemistry, molecular biology, and population genetics, in Advances in Jewish Genetic Diseases. Oxford University Press, New York, 1998.

218.
Beutler E: Molecular biology of G6PD variants and other red cell enzyme defects. Ann Rev Med 43:47, 1992.

219.
Beutler E: Why has the autohemolysis test not gone the way of the cephalin flocculation test? Blood 51:109, 1978.

220.
Carrell RW, Kay R: A simple method for the detection of unstable haemoglobins. Br J Haematol 23:615, 1972.

221.
Lestas AN, Kay LA, Bellingham AJ: Red cell 3-phosphoglycerate level as a diagnostic aid in pyruvate kinase deficiency. Br J Haematol 67:485, 1987.

222.
Valentine WN, Paglia DE, Fink K, Madokoro G: Lead poisoning. Association with hemolytic anemia, basophilic stippling, erythrocyte pyrimidine 5′-nucleotidase deficiency, and intraerythrocytic accumulation of pyrimidines. J Clin Invest 58:926, 1976.

223.
Beutler E: Red blood cell enzymes, in Hematologic Contributions to Fetal Health. Liss, New York, 1988.

224.
Mimouni F, Shohat S, Reisner SH: G6PD-deficiency donor blood as a cause of hemolysis in two preterm infants. Isr J Med Sci 22:120, 1986.

225.
Beutler E, Mathai CK, Smith JE: Biochemical variants of glucose-6-phosphate dehydrogenase giving rise to congenital nonspherocytic hemolytic disease. Blood 31:131, 1968.

226.
Spielberg SP, Boxer LA, Corash LM, Schulman JD: Improved erythrocyte survival with high dose vitamin E in chronic hemolyzing G6PD and glutathione synthetase deficiencies. Ann Intern Med 90:53, 1978.

227.
Corash L, Spielberg S, Bartsocas C, et al: Reduced chronic hemolysis during high-dose vitamin E administration in Mediterranean-type glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 303:416, 1980.

228.
Johnson GJ, Vatassery GT, Finkel B, Allen DW: High-dose vitamin E does not decrease the rate of chronic hemolysis in glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 308:1014, 1983.

229.
Newman JG, Newman TB, Bowie LJ, Mendelsohn J: An examination of the role of vitamin E in glucose-6-phosphate dehydrogenase deficiency. Clin Biochem 12:149, 1979.

230.
Ekert H, Rawlinson I: Deferoxamine and favism. N Engl J Med 312:1260, 1985.

231.
Khalifa AS, El-Alfy MS, Mokhtar G, et al: Effect of desferrioxamine B on hemolysis in glucose-6-phosphate dehydrogenase deficiency. Acta Haematol (Basel) 82:113, 1989.

232.
Zanella A, Berzuini A, Colombo MB, et al: Iron status in red cell pyruvate kinase deficiency: Study of Italian cases. Br J Haematol 83:485, 1993.

233.
Meloni T, Forteleoni G, Noja G, et al: Increased prevalence of glucose-6-phosphate dehydrogenase deficiency in patients with cholelithiasis. Acta Haematol (Basel) 85:76, 1991.

234.
Petrakis NL, Wiesenfeld SL, Sams BJ, et al: Prevalence of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency. N Engl J Med 282:767, 1970.

235.
Bowman HS, McKusick VA, Dronamraju KR: Pyruvate kinase deficient hemolytic anemia in an Amish isolate. Am J Hum Genet 17:1, 1965.

236.
Bianchi M, Magnani M: Hexokinase mutations that produce nonspherocytic hemolytic anemia. Blood Cells Mol Dis 21:2, 1995.

237.
Beutler E: Red Cell Metabolism: A Manual of Biochemical Methods. Grune & Stratton, New York, 1984.

238.
Fujii H, Kanno H, Hirono A, Miwa S: Hematologically important mutations: Molecular abnormalities of glucose-6-phosphate isomerase deficiency. Blood Cells Mol Dis 22:96, 1996.

239.
Beutler E, West C, Britton HA, Harris J, Forman L: Glucosephosphate isomerase (GPI) deficiency mutations associated with hereditary nonspherocytic hemolytic anemia (HNSHA). Blood Cells Mol Dis 23:402, 1997.

240.
Bruno C, Minetti C, Shanske S, et al: Combined defects of muscle phosphofructokinase and AMP deaminase in a child with myoglobinuria. Neurology 50:296, 1998.

241.
Rudolphi O, Ek B, Ronquist G: Inherited phosphofructokinase deficiency associated with hemolysis and exertional myopathy. Eur J Haematol 55:279, 1995.

242.
Kishi H, Mukai T, Hirono A, et al: Human aldolase A deficiency associated with a hemolytic anemia: Thermolabile aldolase due to a single base mutation. Proc Natl Acad Sci USA 84:8623, 1987.

243.
Schneider A, Cohen-Solal M: Hematologically important mutations: Triosephosphate isomerase. Blood Cells Mol Dis 22:82, 1996.

244.
Yoshida A, Twele TW, Dave V, Beutler E: Molecular abnormality of a phosphoglycerate kinase variant (PGK- Alabama). Blood Cells Mol Dis 21:179, 1995.

245.
Turner G, Fletcher J, Elber J, et al: Molecular defect of a phosphoglycerate kinase variant associated with haemolytic anaemia and neurological disorders in a large kindred. Br J Haematol 91:60, 1995.

246.
Lemarchandel V, Joulin V, Valentin C, et al: Compound heterozygosity in a complete erythrocyte bisphosphoglycerate mutase deficiency. Blood 80:2643, 1992.

247.
Beutler E, Gelbart T, Kondo T, Matsunaga AT: The molecular basis of a case of gamma-glutamylcysteine synthetase deficiency. Blood 94:2890, 1999.

248.
Beutler E, Duron O, Kelly BM: Improved method for the determination of blood glutathione. J Lab Clin Med 61:882, 1963.

249.
Beutler E, Gelbart T: Improved assay of the enzymes of glutathione synthesis: gamma-glutamylcysteine synthetase and glutathione synthetase. Clin Chim Acta 158:115, 1986.

250.
Valentine WN, Fink K, Paglia DE, Harris SR, Adams WS: Hereditary hemolytic anemia with human erythrocyte pyrimidine 5′-nucleotidase deficiency. J Clin Invest 54:866, 1974.

251.
Torrance J, West C, Beutler E: A simple rapid radiometric assay for pyrimidine-5′-nucleotidase. J Lab Clin Med 90:563, 1977.

252.
Rees DC, Duley J, Simmonds HA, et al: Interaction of hemoglobin E and pyrimidine 5′ nucleotidase deficiency. Blood 88:2761, 1996.

253.
Chen EH, Tartaglia AP, Mitchell BS: Hereditary overexpression of adenosine deaminase in erythrocytes: Evidence for a cis-acting mutation. Am J Hum Genet 53:889, 1993.

254.
Markert ML: Molecular basis of adenosine deaminase deficiency. Immunodeficiency 5:141, 1994.

255.
Markert ML, Hershfield MS, Wiginton DA, et al: Identification of a deletion in the adenosine deaminase gene in a child with severe combined immunodeficiency. J Immunol 138:3203, 1987.

256.
Manabe J, Arya R, Sumimoto H, et al: Two novel mutations in the reduced nicotinamide adenine dinucleotide (NADH) cytochrome b5 reductase gene of a patient with generalized type, hereditary methemoglobinemia. Blood 88:3208, 1996.

257.
Kaplan J-C, Nicolas A, Hanlickova-Leroux A, Beutler E: A simple spot screening test for fast detection of red cell NADH-diaphorase deficiency. Blood 36:330, 1970.

258.
Jacobasch G, Rapoport SM: Hemolytic anemias due to erythrocyte enzyme deficiencies. Mol Aspects Med 17:143, 1996.

259.
Beutler E, Kuhl W, Gelbart T: Blood cell phosphogluconolactonase: Assay and properties. Br J Haematol 62:577, 1986.

260.
Thorburn DR, Kuchel PW: Computer simulation of the metabolic consequences of the combined deficiency of 6-phosphogluconolactonase and glucose-6-phosphate dehydrogenase in human erythrocytes. J Lab Clin Med 110:70, 1987.

261.
Bird TD, Hamernyik P, Nutter JY, Labbe RF: Inherited deficiency of delta-aminolevulinic acid dehydratase. Am J Hum Genet 31:662, 1979.

262.
Kamatani N, Hakoda M, Otsuka S, Yoshikawa H, Kashiwazaki S: Only three mutations account for almost all defective alleles causing adenine phosphoribosyltransferase deficiency in Japanese patients. J Clin Invest 90:130, 1992.

263.
Cartier P, Hamet M: Une nouvelle maladie metabolique: Le deficit complet en adenine-phosphoribosyltransferase avec lithiase de 2,8-di-hydroxyadenine. C R Acad Sci (Paris) 279:883, 1974.

264.
Hidaka Y, Palella TD, O’Toole TE, Tarle SA, Kelley WN: Human adenine phosphoribosyltransferase. Identification of allelic mutations at the nucleotide level as a cause of complete deficiency of the enzyme. J Clin Invest 80:1409, 1987.

265.
Lachant NA, Zerez CR, Barredo J, et al: Hereditary erythrocyte adenylate kinase deficiency: A defect of multiple phosphotransferases. Blood 77:2774, 1991.

266.
Ogasawara N, Goto H, Yamada Y, Watanabe T: Distribution of AMP-deaminase isozymes in rat tissues. Eur J Biochem 87:297, 1978.

267.
Yamada Y, Makarewicz W, Goto H, et al: Gene mutations responsible for human erythrocyte AMP deaminase deficiency in Poles. Adv Exp Med Biol 431:347, 1998.

268.
Armstrong JM, Myers DV, Verpoorte JA, Edsall JT: Purification and properties of human erythrocyte carbonic anhydrases. J Biol Chem 241:5137, 1966.

269.
Kendall AG, Tashian RE: Erythrocyte carbonic anhydrase I: Inherited deficiency in humans. Science 197:471, 1977.

270.
Roth DE, Venta PJ, Tashian RE, Sly WS: Molecular basis of human carbonic anhydrase II deficiency. Proc Natl Acad Sci USA 89:1804, 1992.

271.
Takahara S: Acatalasemia and hypocatalasemia in the Orient. Semin Hematol 8:397, 1971.

272.
Aebi H, Bossi E, Cantz M, Matsubara S, Suter H: Acatalas(em)ia in Switzerland, in Hereditary Disorders of Erythrocyte Metabolism, p 41. Grune & Stratton, New York, 1968.

273.
Gitzelmann R: Hereditary galactokinase deficiency, a newly recognized cause of juvenile cataracts. Pediatr Res 1:14, 1967.

274.
Beutler E: Galactosemia: Screening and diagnosis. Clin Biochem 24:293, 1991.

275.
Beutler E: Effect of flavin compounds on glutathione reductase activity: In vivo and in vitro studies. J Clin Invest 48:1957, 1969.

276.
McCann SR, Finkel B, Cadman S, Allen DW: Study of a kindred with hereditary spherocytosis and glyceraldehyde-3-phosphate dehydrogenase deficiency. Blood 47:171, 1976.

277.
Valentine WN, Paglia DE, Neerhout RC, Konrad PN: Erythrocyte glyoxalase II deficiency with coincidental hereditary elliptocytosis. Blood 36:797, 1970.

278.
Johnson LA, Gordon RB, Emmerson BT: Hypoxanthine-guanine phosphoribosyltransferase: A simple spectrophotometric assay. Clin Chim Acta 80:203, 1977.

279.
Davidson BL, Tarle SA, Palella TD, Kelley WN: Molecular basis of hypoxanthine-guanine phosphoribosyltransferase deficiency in ten subjects determined by direct sequencing of amplified transcripts. J Clin Invest 84:342, 1989.

280.
Vanderheiden BS: Genetic studies of human erythrocyte inosine triphosphatase. Biochem Genet 3:289, 1969.

281.
Miwa S, Nishina T, Kakehashi Y, et al: Studies on erythrocyte metabolism in a case with hereditary deficiency of H-subunit of lactate dehydrogenase. Acta Haematol Jpn 34:2, 1971.

282.
Sass MD, Caruso CJ, Farhangi M: TPNH-methemoglobin reductase deficiency: A new red-cell enzyme defect. J Lab Clin Med 70:760, 1967.

283.
Kaplan J-C, Alexandre Y, Dreyfus J-C: Deficit selectif d’un des loci genetiques de la phosphoglucomutase dans les globules rouges. C R Acad Sci (Paris) 270:1060, 1970.

284.
Chamberlain BR, Buttery JE: Reappraisal of the uroporphyrinogen I synthase assay, and a proposed modified method. Clin Chem 26:1346, 1980.

285.
Strand LJ, Meyer UA, Felsher BF, Redeker AG, Marver HS: Decreased red cell uroporphyrinogen I synthetase activity in intermittent acute porphyria. J Clin Invest 51:2530, 1972.

286.
Nafa K, Reghis A, Osmani N, et al: G6PD Aures: A new mutation (48 Ile®hr) causing mild G6PD deficiency is associated with favism. Hum Mol Genet 2:81, 1993.

287.
Beutler E, Kuhl W, Ramirez E, Lisker R: Some Mexican glucose-6-phosphate dehydrogenase (G-6-PD) variants revisited. Hum Genet 86:371, 1991.

288.
Vulliamy TJ, D’Urso M, Battistuzzi G, et al: Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. Proc Natl Acad Sci USA 85:5171, 1988.

289.
Cappellini MD, Martinez di Montemuros F, Dotti C, et al: Molecular characterisation of the glucose-6-phosphate dehydrogenase (G6PD) Ferrara II variant. Hum Genet 95:440, 1995.

290.
Beutler E, Kuhl W, Saáenz GF, Rodriguez W: Mutation analysis of G6PD variants in Costa Rica. Hum Genet 87:462, 1991.

291.
Beutler E, Kuhl W: The NT 1311 polymorphism of G6PA: G6PD Mediterranean mutation may have originated independently in Europe and Asia. Am J Hum Genet 47:1008, 1990.

292.
De Vita G, Alcalay M, Sampietro M, et al: Two point mutations are responsible for G6PD polymorphism in Sardinia. Am J Hum Genet 44:233, 1989.

293.
Ninfali P, Bresolin N, Baronciani L, et al: Glucose-6-phosphate dehydrogenase Lodi844C: A study on its expression in blood cells and muscle. Enzyme 45:180, 1991.

294.
Beutler E, Prchal JT, Westwood B, Kuhl W: Definition of the mutations of G6PD Wayne, G6PD Viangchan, G6PD Jammu and G6PD “LeJeune.” Acta Haematol (Basel) 86:179, 1991.

295.
Beutler E, Westwood B, Prchal J, et al: New glucose-6-phosphate dehydrogenase mutations from various ethnic groups. Blood 80:255, 1992.

296.
Vlachos A, Westwood B, Lipton JM, Beutler E: G6PD Mt. Sinai. A new severe hemolytic variant characterized by dual mutations at nucleotides 376 and 1159. Hum Mutat 6 (suppl 1):S154, 1998.

297.
Filosa S, Calabrò V, Vallone D, et al: Molecular basis of chronic non-spherocytic haemolytic anaemia: A new G6PD variant (393 Arg®His) with abnormal KmGPD and marked instability. Br J Haematol 80:111, 1992.

298.
Chiu DTY, Zuo L, Chen E, Chang CN, Chiu DTY: Two commonly occurring nucleotide base substitutions in Chinese G6PD variants. Biochem Biophys Res Commun 180:988, 1991.

299.
Stevens DJ, Wanachiwanawin W, Mason PJ, Vulliamy TJ, Luzzatto L: G6PD Canton a common deficient variant in South East Asia caused by a 459 Arg®Leu mutation. Nucl Acids Res 18:7190, 1990.

300.
Calabrò V, Mason PJ, Filosa S, et al: Genetic heterogeneity of glucose-6-phosphate dehydrogenase deficiency revealed by single-strand conformation and sequence analysis. Am J Hum Genet 52:527, 1993.

301.
Neubauer B, Lakomek M, Winkler H, et al: Point mutations in the L-type pyruvate kinase gene of two children with hemolytic anemia caused by pyruvate kinase deficiency. Blood 77:1871, 1991.

302.
Kanno H, Fujii H, Hirono A, Miwa S: cDNA cloning of human R-type pyruvate kinase and identification of a single amino acid substitution (Thr384®Met) affecting enzymatic stability in a pyruvate kinase variant (PK Tokyo) associated with hereditary hemolytic anemia. Proc Natl Acad Sci USA 88:8218, 1991.

303.
Kanno H, Fujii H, Hirono A, Omine M, Miwa S: Identical point mutations of the R-type pyruvate kinase (PK) cDNA found in unrelated PK variants associated with hereditary hemolytic anemia. Blood 79:1347, 1992.

304.
Gerr F, Frumkin H, Hodgins A: Hemolytic anemia following succimer administration in a glucose-6-phosphate dehydrogenase deficient patient. J Toxicol Clin Toxicol 32:569, 1994.

305.
Rajkondawar VL, Modi TH, Mishra SN: Drug induced acute haemolytic anaemia in glucose-6-phosphate dehydrogenase deficiency subjects. J Assoc Physicians (India) 16:589, 1968.

306.
Omar MES, Wahab MFA: Treatment of typhoid and paratyphoid fever with furazolidone. J Trop Med Hyg 70:43, 1967.

307.
Teunis BS, Leftwich EI, Pierce LE: Acute methemoglobinemia and hemolytic anemia due to toluidine blue. Arch Surg 101:527, 1970.

308.
Meloni G, Meloni T: Glyburide-induced acute haemolysis in a G6PD-deficient patient with NIDDM. Br J Haematol 92:159, 1996.

309.
Little C, Schacter B: Hemolytic anemia following isobutyl nitrate (IBN) inhalation in a patient with glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Blood 54(suppl 1):34A, 1979.

310.
Rosen PJ, Johnson C, McGehee WG, Beutler E: Failure of methylene blue treatment in toxic methemoglobinemia. Association with glucose-6-phosphate dehydrogenase deficiency. Ann Intern Med 75:83, 1971.

311.
Belton EM, Jones RV: Haemolytic anaemia due to nalidixic acid. Lancet 2:691, 1965.

312.
Mandal BK, Stevenson J: Haemolytic crisis produced by nalidixic acid. Lancet 1:614, 1970.

313.
Djerassi LS, Vitany L: Haemolytic episode in G6PD deficient workers exposed to TNT. Br J Ind Med 32:54, 1975.

314.
Melzer-Lange M, Walsh-Kelly C: Naphthalene-induced hemolysis in a black female toddler deficient in glucose-6-phosphate dehydrogenase. Pediatr Emerg Care 5:24, 1989.

315.
Todisco V, Lamour J, Finberg L: Hemolysis from exposure to naphthalene mothballs. N Engl J Med 325:1660, 1991.

316.
Ducros J, Saingra S, Rampal M, et al: Hemolytic anemia due to G6PD deficiency and urate oxidase in a kidney-transplant patient. Clin Nephrol 35:89, 1991.

317.
Lapierre J, Holler C, Tourte-Schaefer C, et al: Haemolytic anaemia following anti-bilharzia treatment using niridazole in a woman of caribbean origin with GPD deficiency. Nouv Presse Med 5:147, 1976.

318.
Thomas M, Agnus D, Poirot JL, Golvan YJ: Hemolysis induced by niridazole in two patients with deficiency of G-6-PD. Nouv Presse Med 5:1537, 1976.

319.
Chan TK, Todd D, Tso SC: Drug-induced haemolysis in glucose-6-phosphate dehydrogenase deficiency. BMJ 2:1227, 1976.

320.
Tishler M: Phenazopyridine-induced hemolytic anemia in a patient with G-6-PD deficiency. Acta Haematol (Basel) 70:208, 1983.

321.
Chan TK, Todd D, Tso SC: Red cell survival studies in glucose-6-phosphate dehydrogenase deficiency. Bull Hong Kong Med Assoc 26:41, 1974.

322.
Herman J, Ben-Meir S: Overt hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency. Isr J Med Sci 2:340, 1975.

323.
Gaetani GD, Mareni C, Ravazzolo R, Salvidio E: Haemolytic effect of two sulphonamides evaluated by a new method. Br J Haematol 32:183, 1976.

324.
McCurdy PR, Donohoe RF: Pyridoxine-responsive anemia conditioned by isonicotinic acid hydrazide. Blood 27:352, 1966.

325.
Gaetani G, Salvidio E, Pannacciulli I, Ajmar F, Paravidino G: Absence of haemolytic effects of L-DOPA on transfused G6PD-deficient erythrocytes. Experientia 26:785, 1970.

326.
Zail SS, Charlton RW, Bothwell TH: The haemolytic effect of certain drugs in Bantu subjects with a deficiency of glucose-6-phosphate dehydrogenase. S Afr J Med Sci 27:95, 1962.

327.
Heinrich RA, Smith TC, Buchanan RA: A pharmacological study of a new sulfonamide in glucose-6-phosphate dehydrogenase deficient subjects. J Clin Pharmacol 11:428, 1971.

328.
Szeinberg A, Pras M, Sheba C, Adam A, Ramot B: The hemolytic effect of various sulfonamides on subjects with a deficiency of glucose-6-phosphate dehydrogenase of erythrocytes. Isr J Med Sci 18:176, 1959.

329.
Kellermeyer RW, Tarlov AR, Schrier SL, Alving AS: Hemolytic effect of commonly used drugs on erythrocytes deficient in glucose-6-phosphate dehydrogenase. J Lab Clin Med 52:827, 1958.

330.
Kellermeyer RW, Tarlov AR, Brewer GJ, Carson PE, Alving AS: Hemolytic effect of therapeutic drugs. Clinical considerations of the Primaquine-type hemolysis. JAMA 180:388, 1962.

331.
Mela Q, Perpignano G, Ruggiero V, Longatti S: Tolerability of tiaprofenic acid in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Drugs 35:107, 1988.

332.
Beutler E, Gelbart T: Estimating the prevalence of pyruvate kinase deficiency from the gene frequency in the general white population. Blood 95:3585, 2000.
Books@Ovid
Copyright © 2001 McGraw-Hill
Ernest Beutler, Marshall A. Lichtman, Barry S. Coller, Thomas J. Kipps, and Uri Seligsohn
Williams Hematology

Advertisements

3 comments on “CHAPTER 45 GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY AND OTHER RED CELL ENZYME ABNORMALITIES

  1. […] CHAPTER 45 GLUCOSE-6-PHOSPHATE DEHYDROGENASE … […]

  2. annual startrak reappraisal carteloise nusic predictable griffon leilani airway

  3. After study a number of of the weblog posts in your web site now, and I actually like your method of blogging. I bookmarked it to my bookmark website listing and will likely be checking again soon. Pls take a look at my web page as effectively and let me know what you think.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: